[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 232
1. Roy S, Josephson SA, Fridlyand J, Karch J, Kadoch C, Karrim J, Damon L, Treseler P, Kunwar S, Shuman MA, Jones T, Becker CH, Schulman H, Rubenstein JL: Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol; 2008 Jan 1;26(1):96-105
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein biomarker identification in the CSF of patients with CNS lymphoma.
  • PURPOSE: Elucidation of the CSF proteome may yield insights into the pathogenesis of CNS disease.
  • We tested the hypothesis that individual CSF proteins distinguish CNS lymphoma from benign focal brain lesions.
  • METHODS: We used a liquid chromatography/mass spectrometry-based method to differentially quantify and identify several hundred CSF proteins in CNS lymphoma and control patients.
  • ATIII RNA transcripts were identified within CNS lymphomas, and ATIII protein was localized selectively to tumor neovasculature.
  • We propose that the discovery of CSF protein biomarkers will facilitate early and noninvasive diagnosis in patients with lesions not amenable to brain biopsy, as well as provide improved surrogates of prognosis and treatment response in CNS lymphoma and brain metastasis.
  • [MeSH-major] Biomarkers, Tumor / cerebrospinal fluid. Brain Neoplasms / cerebrospinal fluid. Lymphoma / cerebrospinal fluid. Neoplasm Proteins / cerebrospinal fluid
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antithrombin III / genetics. Antithrombin III / metabolism. Case-Control Studies. Chromatography, Liquid. Diagnosis, Differential. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunoblotting. Immunoenzyme Techniques. Leukemia, Myeloid / cerebrospinal fluid. Leukemia, Myeloid / pathology. Lymphoma, B-Cell / cerebrospinal fluid. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell, Marginal Zone / cerebrospinal fluid. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Large B-Cell, Diffuse / cerebrospinal fluid. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Non-Hodgkin / cerebrospinal fluid. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Proteomics. Sensitivity and Specificity. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Feb;17(2):554-60 [10080599.001]
  • [Cites] Bioinformatics. 2004 Dec 12;20(18):3575-82 [15284095.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5034-43 [15955902.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Aug;19(4):705-17, vii [16083831.001]
  • [Cites] Mol Cell Proteomics. 2005 Sep;4(9):1341-9 [15970584.001]
  • [Cites] Dis Markers. 2006;22(1-2):3-26 [16410649.001]
  • [Cites] Blood. 2006 May 1;107(9):3716-23 [16418334.001]
  • [Cites] J Biol Chem. 2006 Dec 8;281(49):37302-10 [17040907.001]
  • [Cites] Expert Rev Mol Med. 2006;8(31):1-19 [17156576.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Anal Chem. 2003 Sep 15;75(18):4818-26 [14674459.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):266-72 [12525518.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):2053-63 [12466122.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Curr Opin Neurol. 2000 Dec;13(6):641-8 [11148663.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):864-71 [9508167.001]
  • [Cites] Clin Chem. 1993 Apr;39(4):561-77 [8472349.001]
  • [Cites] Br J Haematol. 2004 Jul;126(2):202-8 [15238140.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):2922-7 [15131026.001]
  • [Cites] Bioinformatics. 2004 Mar 22;20(5):777-85 [14751995.001]
  • [Cites] J Neurosurg. 2007 Jan;106(1):72-5 [17236490.001]
  • [CommentIn] J Clin Oncol. 2009 May 1;27(13):2302-3; author reply 2303-4 [19332721.001]
  • (PMID = 18056677.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA100291
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 9000-94-6 / Antithrombin III
  • [Other-IDs] NLM/ NIHMS612770; NLM/ PMC4134101
  •  go-up   go-down


2. Taylor AJ, Little MP, Winter DL, Sugden E, Ellison DW, Stiller CA, Stovall M, Frobisher C, Lancashire ER, Reulen RC, Hawkins MM: Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study. J Clin Oncol; 2010 Dec 20;28(36):5287-93
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study.
  • PURPOSE: CNS tumors are the most common second primary neoplasm (SPN) observed after childhood cancer in Britain, but the relationship of risk to doses of previous radiotherapy and chemotherapy is uncertain.
  • Linkage to national, population-based cancer registries identified 247 SPNs of the CNS.
  • RESULTS: There were 137 meningiomas, 73 gliomas, and 37 other CNS neoplasms included in the analysis.
  • The risk of glioma/primitive neuroectodermal tumors increased linearly with dose of radiation, and those who had CNS tissue exposed to at least 40 Gy experienced a risk four-fold that experienced by those who had CNS tissue unexposed.
  • CONCLUSION: The largest-ever study, to our knowledge, of CNS tumors in survivors of childhood cancer indicates that the risk of meningioma increases rapidly with increased dose of radiation to meningeal tissue and with increased dose of intrathecal methotrexate.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21079138.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / ZIA CP010131-18; United Kingdom / Cancer Research UK / / ; United Kingdom / Department of Health / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ NIHMS533866; NLM/ PMC4809645
  •  go-up   go-down


3. Panchal NJ, Niku S, Imbesi SG: Lymphocytic vasculitis mimicking aggressive multifocal cerebral neoplasm: mr imaging and MR spectroscopic appearance. AJNR Am J Neuroradiol; 2005 Mar;26(3):642-5
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphocytic vasculitis mimicking aggressive multifocal cerebral neoplasm: mr imaging and MR spectroscopic appearance.
  • We present a case of multifocal enhancing lesions confined to the right cerebral hemisphere that mimicked diffuse neoplasm.
  • Biopsy showed lymphocytic vasculitis, a rare variant of primary angiitis of the CNS.
  • [MeSH-major] Brain Neoplasms / diagnosis. Lymphocytes / pathology. Magnetic Resonance Imaging. Magnetic Resonance Spectroscopy. Vasculitis, Central Nervous System / diagnosis
  • [MeSH-minor] Adult. Brain / metabolism. Brain / pathology. Choline / metabolism. Diagnosis, Differential. Female. Glutamic Acid / metabolism. Glutamine / metabolism. Humans


Advertisement
4. Chi SN, Zimmerman MA, Yao X, Cohen KJ, Burger P, Biegel JA, Rorke-Adams LB, Fisher MJ, Janss A, Mazewski C, Goldman S, Manley PE, Bowers DC, Bendel A, Rubin J, Turner CD, Marcus KJ, Goumnerova L, Ullrich NJ, Kieran MW: Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol; 2009 Jan 20;27(3):385-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor.
  • PURPOSE: Atypical teratoid rhabdoid tumor (ATRT) of the CNS is a highly malignant neoplasm primarily affecting young children, with a historic median survival ranging from 6 to 11 months.
  • Based on a previous pilot series, a prospective multi-institutional trial was conducted for patients with newly diagnosed CNS ATRT.
  • Gross total resection of the primary tumor was achieved in 11 patients.
  • CONCLUSION: This intensive multimodality regimen has resulted in a significant improvement in time to progression and overall survival for patients with this previously poor-prognosis tumor.
  • [MeSH-major] Brain Neoplasms / therapy. Rhabdoid Tumor / therapy. Teratoma / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Humans. Infratentorial Neoplasms. Prognosis. Prospective Studies. Supratentorial Neoplasms. Young Adult

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Hematol Oncol. 2002 Jun-Jul;24(5):337-42 [12142780.001]
  • [Cites] Pediatr Blood Cancer. 2008 Aug;51(2):235-40 [18381756.001]
  • [Cites] Radiology. 1969 Dec;93(6):1351-9 [4983156.001]
  • [Cites] Hum Pathol. 1987 Apr;18(4):332-7 [3030922.001]
  • [Cites] Pediatr Neurol. 1991 Jul-Aug;7(4):237-42 [1930413.001]
  • [Cites] Med Pediatr Oncol. 1992;20(3):258 [1637409.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 Feb;17(1):71-5 [7743242.001]
  • [Cites] J Neurooncol. 1995;24(1):21-8 [8523069.001]
  • [Cites] J Neurosurg. 1996 Jul;85(1):56-65 [8683283.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1013-9 [9719110.001]
  • [Cites] Am J Surg Pathol. 1998 Sep;22(9):1083-92 [9737241.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1491-9 [15735125.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):978-86 [15758008.001]
  • [Cites] J Neurooncol. 2005 Mar;72(1):77-84 [15803379.001]
  • [Cites] Pediatr Blood Cancer. 2005 May;44(5):478-86 [15918215.001]
  • [Cites] Neurosurg Focus. 2005 Jun 15;18(6A):E8 [16048294.001]
  • [Cites] J Neurooncol. 2007 Jan;81(1):97-111 [16855864.001]
  • [Cites] J Pediatr Psychol. 2007 Sep;32(8):918-25 [17522113.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7):928-40 [17066459.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2877-84 [15254056.001]
  • (PMID = 19064966.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA046274; United States / NCI NIH HHS / CA / R01 CA046274-17A2; United States / NCI NIH HHS / CA / CA46274
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2645855
  •  go-up   go-down


5. Pels H, Montesinos-Rongen M, Schaller C, Schlegel U, Schmidt-Wolf IG, Wiestler OD, Deckert M: VH gene analysis of primary CNS lymphomas. J Neurol Sci; 2005 Feb 15;228(2):143-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VH gene analysis of primary CNS lymphomas.
  • Primary CNS lymphomas (PCNSL) are highly malignant non-Hodgkin's lymphomas of B cell origin associated with a poor prognosis.
  • These neoplasms show variable sensitivity to radio- and chemotherapy.
  • A molecular basis for these differences in treatment responses has not yet been established for primary CNS lymphomas in a comprehensive series of patients.
  • [MeSH-major] Brain Neoplasms / genetics. Drug Resistance, Neoplasm / genetics. Gene Rearrangement, B-Lymphocyte / genetics. Genes, Immunoglobulin / genetics. Immunoglobulins / genetics. Lymphoma, Non-Hodgkin / genetics
  • [MeSH-minor] Adult. Aged. DNA Mutational Analysis. Disease Progression. Female. Gene Frequency. Genetic Markers / genetics. Genetic Markers / immunology. Genetic Predisposition to Disease / genetics. Genetic Testing. Humans. Male. Middle Aged. Mutation / genetics. Predictive Value of Tests. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15694195.001).
  • [ISSN] 0022-510X
  • [Journal-full-title] Journal of the neurological sciences
  • [ISO-abbreviation] J. Neurol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / Immunoglobulins
  •  go-up   go-down


6. Pestalozzi BC, Francis P, Quinaux E, Dolci S, Azambuja E, Gelber RD, Viale G, Balil A, Andersson M, Nordenskjöld B, Gnant M, Gutierrez J, Láng I, Crown JP, Piccart-Gebhart M, BIG 02-98 Collaborative Group: Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial. Ann Oncol; 2008 Nov;19(11):1837-41
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial.
  • BACKGROUND: Breast cancer central nervous system (CNS) metastases are an increasingly important problem because of high CNS relapse rates in patients treated with trastuzumab and/or taxanes.
  • After a median follow-up of 5 years, 403 patients had died and detailed information on CNS relapse was collected for these patients.
  • RESULTS: CNS relapse occurred in 4.0% of control patients and 3.7% of docetaxel-treated patients.
  • CNS relapse occurred in 27% of deceased patients in both treatment groups.
  • CNS relapse was usually accompanied by neurologic symptoms (90%), and 25% of patients with CNS relapse died without evidence of extra-CNS relapse.
  • Only 20% of patients survived 1 year from the diagnosis of CNS relapse.
  • Prognosis of CNS relapse was worse for patients with meningeal carcinomatosis when compared with brain metastases.
  • CONCLUSION: There is no evidence that adjuvant docetaxel treatment is associated with an increased frequency of CNS relapse.

  • Genetic Alliance. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2006 Jun;17(6):935-44 [16603601.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1133-44 [17675394.001]
  • [Cites] J Natl Cancer Inst. 2008 Jan 16;100(2):121-33 [18182617.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(11):2349-51 [10829059.001]
  • [Cites] Ann Oncol. 2001 Mar;12(3):353-6 [11332148.001]
  • [Cites] Ann Oncol. 2005 Nov;16(11):1772-7 [16150805.001]
  • [Cites] Cancer. 2004 Oct 15;101(8):1760-6 [15386311.001]
  • [Cites] Cancer. 1995 Jul 15;76(2):232-6 [8625097.001]
  • [Cites] Breast Cancer Res Treat. 2004 Dec;88(3):273-80 [15609130.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):44-55 [15630443.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1687-717 [15894097.001]
  • [Cites] Cancer. 2003 Jun 15;97(12):2972-7 [12784331.001]
  • (PMID = 18562328.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-73362
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC2733076
  •  go-up   go-down


7. Chu LC, Eberhart CG, Grossman SA, Herman JG: Epigenetic silencing of multiple genes in primary CNS lymphoma. Int J Cancer; 2006 Nov 15;119(10):2487-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic silencing of multiple genes in primary CNS lymphoma.
  • Primary central nervous system lymphoma (PCNSL) is an increasingly common tumor that has not been extensively examined for changes in promoter region methylation.
  • We examined 14 tumor suppressor genes in 25 cases of PCNSL using methylation-specific PCR.
  • Methylation of DAPK, p16(INK) (4a) or MGMT was found in 96% of the tumors, suggesting simple marker strategies to detect circulating methylated DNA in serum that might facilitate early tumor detection.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Epigenesis, Genetic. Gene Silencing. Genes, Tumor Suppressor. Lymphoma / genetics
  • [MeSH-minor] Adult. Aged. DNA Methylation. DNA, Neoplasm / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Middle Aged. Promoter Regions, Genetic


8. Carson KA, Grossman SA, Fisher JD, Shaw EG: Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol; 2007 Jun 20;25(18):2601-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials.
  • The studies had similar inclusion criteria and were conducted within the New Approaches to Brain Tumor Therapy CNS Consortium.
  • RESULTS: Factors associated with an increased risk of death were increased age, lower Karnofsky performance score (KPS), initial and on-study histologies of glioblastoma multiforme (GBM), corticosteroid use, shorter time from original diagnosis to recurrence, and tumor outside frontal lobe.
  • Median survival time was poorest in non-GBM patients with KPS less than 80 or GBM patients, age 50 years, corticosteroid use (4.4 months; 95% CI, 3.6 to 5.4 months); median survival was best in patients with initial histology other than GBM with KPS 80 and tumor confined to the frontal lobe (25.7 months; 95% CI, 18.7 to 52.5), and was 7.0 months (95% CI, 6.2 to 8.0 months) for all patients.

  • Genetic Alliance. consumer health - Glioma.
  • Genetic Alliance. consumer health - Brain Tumor, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3260-6 [11432894.001]
  • [Cites] Neuro Oncol. 2000 Jan;2(1):29-33 [11302251.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Front Radiat Ther Oncol. 1999;33:150-7 [10549485.001]
  • [Cites] J Clin Oncol. 2007 Feb 1;25(4):399-404 [17264335.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5174-81 [16951236.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):177-82 [15831235.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Neuro Oncol. 2005 Jan;7(1):32-40 [15701280.001]
  • [Cites] Anticancer Res. 1998 Mar-Apr;18(2B):1303-11 [9615807.001]
  • [Cites] Acta Oncol. 1996;35 Suppl 8:123-7 [9073058.001]
  • [Cites] J Clin Epidemiol. 1995 May;48(5):675-89 [7730923.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2267-76 [11980997.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1845-9 [12721262.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2940-9 [12912940.001]
  • [Cites] J Neurosurg. 2003 Aug;99(2):297-303 [12924704.001]
  • [Cites] Strahlenther Onkol. 2003 Sep;179(9):615-9 [14628127.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):21-7 [14769136.001]
  • [Cites] Neuro Oncol. 2004 Jul;6(3):227-35 [15279715.001]
  • [Cites] Mol Ther. 2004 Nov;10(5):958-66 [15509513.001]
  • [Cites] J Clin Oncol. 1983 Jan;1(1):38-44 [6321671.001]
  • [Cites] Acta Oncol. 1989;28(1):51-5 [2539846.001]
  • [CommentIn] J Clin Oncol. 2012 Feb 10;30(5):562-3; author reply 563-4 [22215743.001]
  • (PMID = 17577040.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062475; United States / NCI NIH HHS / CA / CA62475
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS507874; NLM/ PMC4118746
  •  go-up   go-down


9. Morris EB, Gajjar A, Okuma JO, Yasui Y, Wallace D, Kun LE, Merchant TE, Fouladi M, Broniscer A, Robison LL, Hudson MM: Survival and late mortality in long-term survivors of pediatric CNS tumors. J Clin Oncol; 2007 Apr 20;25(12):1532-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and late mortality in long-term survivors of pediatric CNS tumors.
  • PURPOSE: To describe the pattern of survival and late mortality among contemporary long-term survivors of pediatric CNS tumor.
  • PATIENTS AND METHODS: The study population comprised 643 pediatric patients with primary CNS tumor treated at St Jude Children's Research Hospital (Memphis, TN) from 1985 to 2000 who survived > or = 5 years from diagnosis.
  • Patients were classified according to primary tumor type, location of tumor, and survival.
  • A significant difference in the survival rates according to original tumor type (P = .001) was seen.
  • Sixty-six (10%) of 643 patients experienced late mortality: 38 patients (58%) died of progressive disease while 14 patients (21%) died of second malignant tumor.
  • Twelve patients (18%), predominantly with diencephalic tumor location, died of a specific medical cause: cardiovascular disease (n = 2), cerebrovascular accident (n = 1), metabolic collapse and/or sepsis (n = 7), respiratory failure (n = 1), or shunt malfunction (n = 1).
  • CONCLUSION: Late mortality occurs in a substantial number of long-term survivors of pediatric CNS tumors and is most influenced by the initial tumor histopathology.
  • [MeSH-major] Cause of Death. Central Nervous System Neoplasms / mortality. Survivors / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Child. Child, Preschool. Cohort Studies. Disease Progression. Disease-Free Survival. Female. Humans. Incidence. Male. Neoplasm Staging. Prognosis. Registries. Retrospective Studies. Risk Assessment. Sex Distribution. Survival Analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17442996.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA 21765
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Fischer L, Martus P, Weller M, Klasen HA, Rohden B, Röth A, Storek B, Hummel M, Nägele T, Thiel E, Korfel A: Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients. Neurology; 2008 Sep 30;71(14):1102-8
Zurich Open Access Repository and Archive. Full text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients.
  • BACKGROUND: The impact of meningeal dissemination in primary CNS lymphoma (PCNSL) is debated, and the reported frequency varies.
  • CONCLUSIONS: We found a low rate of meningeal dissemination in primary CNS lymphoma in this large prospective study.
  • [MeSH-major] Lymphoma / diagnosis. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / secondary. Neoplasm Metastasis / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain / pathology. Cell Count / statistics & numerical data. Combined Modality Therapy. Cytological Techniques / statistics & numerical data. Female. Humans. Immunoglobulin Heavy Chains / analysis. Immunoglobulin Heavy Chains / blood. Magnetic Resonance Imaging / statistics & numerical data. Male. Meninges / pathology. Middle Aged. Polymerase Chain Reaction / statistics & numerical data. Predictive Value of Tests. Prospective Studies. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18824675.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


11. Miletic B, Morovic M, Tomic Z, Ticac B: [Tuberculous orchiepididymitis and CNS complication]. Aktuelle Urol; 2006 Jan;37(1):67-8
MedlinePlus Health Information. consumer health - Hydrocephalus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tuberculous orchiepididymitis and CNS complication].
  • CONCLUSIONS: Urogenital system is at the present rarely affected by Tbc.
  • Disseminated Tbc presented with many different but non-specific clinical symptoms, sometimes mimicking neoplasm.
  • [MeSH-major] Epididymitis / complications. Hydrocephalus / etiology. Orchitis / complications. Tuberculosis, Central Nervous System / etiology. Tuberculosis, Male Genital / complications. Tuberculosis, Miliary / complications
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440250.001).
  • [ISSN] 0001-7868
  • [Journal-full-title] Aktuelle Urologie
  • [ISO-abbreviation] Aktuelle Urol
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Holfort SK, Lindegaard J, Isager P, Prause JU, Heegaard S: CNS metastasis from malignant uveal melanoma: a clinical and histopathological characterisation. Br J Ophthalmol; 2009 May;93(5):641-4
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS metastasis from malignant uveal melanoma: a clinical and histopathological characterisation.
  • AIM: To characterise uveal melanoma that has metastasised to the central nervous system (CNS).
  • All patients with malignant uveal melanoma and metastasis to the CNS were identified.
  • RESULTS: Sixteen patients with CNS metastasis were identified.
  • The majority of CNS metastases were located in the frontal and parietal lobes.
  • Five patients had exclusively metastasis to the CNS.
  • The average time from diagnosis of primary tumour to symptoms of CNS metastasis was 91 months.
  • The average time from the initial CNS symptoms to death was 20 months.
  • CONCLUSION: The proportion of uveal melanoma patients having CNS metastasis was 0.7%.
  • Eleven patients had multiple organ metastases, and the average time from the initial CNS symptoms to death was 8 months.
  • Five patients had metastasis to the CNS solely, and the average time from the initial CNS symptoms to death was 57 months.
  • [MeSH-major] Brain Neoplasms / secondary. Melanoma / secondary. Uveal Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Denmark / epidemiology. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Registries. Time Factors. Young Adult

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19091854.001).
  • [ISSN] 1468-2079
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


13. Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Islam R, Aldape KD, Yu TK, Hortobagyi GN, Gonzalez-Angulo AM: Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol; 2008 Jul;19(7):1242-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defining prognosis for women with breast cancer and CNS metastases by HER2 status.
  • BACKGROUND: The purpose of this retrospective study was to determine, in a cohort of patients with breast cancer and central nervous system (CNS) metastases, the effect of trastuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive disease and to compare this with that of patients with HER2-negative disease.
  • METHODS: Five hundred and ninety-eight patients with invasive breast cancer, CNS metastases and known HER2 status were identified.
  • Time to CNS metastases and survival after CNS metastases were estimated by the Kaplan-Meier method, and Cox models were fitted to determine the association between HER2 status, trastuzumab treatment and outcomes after adjustment for other patient characteristics.
  • RESULTS: In the multivariable model, patients with HER2-negative disease [Hazard ratio (HR) 1.50, 95% confidence interval (CI) 1.15-1.95, P = 0.003] and patients with HER2-positive disease who did not receive trastuzumab (HR 2.13, 95% CI 1.51-3.00, P < 0.0001) had shorter times to CNS metastases compared with patients with HER2-positive disease who had received trastuzumab as first-line therapy for metastases.
  • Furthermore, patients with HER2-negative disease (HR 1.66, 95% CI 1.31-2.12, P < 0.0001) and patients with HER2-positive disease who had never received trastuzumab (HR 1.34, 95% CI 0.78-2.30, P = 0.28) had an increased hazard of death compared with patients with HER2-positive disease who had received trastuzumab before or at the time of CNS metastases diagnosis.
  • CONCLUSION: In our cohort of patients with breast cancer and CNS metastases, patients with HER2-positive disease treated with trastuzumab had longer times to development of and better survival from CNS metastases compared with patients with HER2-positive disease who had never received trastuzumab and patients with HER2-negative breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18334512.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K23CA121994-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down


14. Murray G, Jiménez L, Báez F, Colón-Castillo LE, Brau RH: Descriptive profile of surgically-confirmed adult central nervous system tumors in Puerto Rico. P R Health Sci J; 2009 Dec;28(4):317-28

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Descriptive profile of surgically-confirmed adult central nervous system tumors in Puerto Rico.
  • INTRODUCTION: Published studies regarding the incidence of central nervous system (CNS) tumors in Puerto Rico (PR) are exceedingly rare.
  • The general understanding is that the incidence of these tumors in Puerto Rico is similar to the one found in the United States of America (USA).
  • The objective of this study is to describe the specific profile of all the CNS tumors that are surgically intervened in Puerto Rico, through the creation of a database.
  • METHODS: A retrospective analysis of all the surgical procedures from January 1, 2002 to May 31, 2006 for adult CNS tumors in Puerto Rico was performed.
  • The information was organized to form a database of all the CNS neoplasms.
  • RESULTS: A total of 1,018 procedures for CNS tumors were performed on 1,005 patients.
  • The incidence rate of surgically intervened CNS tumors in Puerto Rico is 6 per 100,000 people.
  • CNS tumors were more common in women than in men (58% vs. 42%), respectively.
  • CONCLUSIONS: Our results reflect a unique histopathological distribution of operated CNS tumors in Puerto Rico.
  • In this series, primary tumors are more common than metastatic tumors.
  • Benign histological tumors were more frequent than more malignant variants.
  • Although this study reflects only the histologically diagnosed tumors, it is headway towards diagnosing the incidence of all CNS tumors in Puerto Rico.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Central Nervous System Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Puerto Rico. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19999240.001).
  • [ISSN] 0738-0658
  • [Journal-full-title] Puerto Rico health sciences journal
  • [ISO-abbreviation] P R Health Sci J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Puerto Rico
  •  go-up   go-down


15. Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, Casasnovas O, Dupriez B, Souleau B, Taksin AL, Gisselbrecht C, Jaccard A, Omuro A, Sanson M, Janvier M, Kolb B, Zini JM, Leblond V, Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire: Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol; 2008 May 20;26(15):2512-8
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
  • PURPOSE: The prognosis of relapsing primary CNS lymphoma (PCNSL) is poor.
  • We report the results of a prospective multicenter trial of intensive chemotherapy followed by autologous hematopoietic stem-cell rescue (IC + HCR) in immunocompetent adult patients with PCNSL or intraocular lymphoma (IOL) after failure of high-dose methotrexate-based treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Eye Neoplasms / therapy. Hematopoietic Stem Cell Transplantation. Lymphoma, Large B-Cell, Diffuse / therapy. Neoplasm Recurrence, Local / therapy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Busulfan / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Prospective Studies. Survival Rate. Thiotepa / administration & dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18413641.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; 905Z5W3GKH / Thiotepa; G1LN9045DK / Busulfan
  •  go-up   go-down


16. Jahnke K, Hummel M, Korfel A, Burmeister T, Kiewe P, Klasen HA, Müller HH, Stein H, Thiel E: Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes. J Clin Oncol; 2006 Oct 10;24(29):4754-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes.
  • PURPOSE: To search for subclinical systemic disease in bone marrow and peripheral blood in patients with primary CNS lymphoma (PCNSL) to elucidate whether extracerebral relapse may represent a sequel of initial occult systemic disease rather than true extracerebral spread.
  • RESULTS: Identical dominant PCR products were found in bone marrow aspirates, blood samples, and tumor biopsy specimens of two patients, indicating that the same tumor cell population is present in the CNS and in extracerebral sites.
  • An oligoclonal IgH rearrangement pattern was found in the tumor specimen of two other patients, whereas bone marrow and blood samples demonstrated the same dominant PCR products.
  • [MeSH-major] Bone Marrow Neoplasms / diagnosis. Brain Neoplasms / diagnosis. Immunoglobulin Heavy Chains / genetics. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Marrow / chemistry. Female. Gene Rearrangement. Humans. Male. Middle Aged. Neoplasm Staging / methods. Polymerase Chain Reaction. Recurrence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16966685.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


17. Rubenstein JL, Fridlyand J, Abrey L, Shen A, Karch J, Wang E, Issa S, Damon L, Prados M, McDermott M, O'Brien J, Haqq C, Shuman M: Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol; 2007 Apr 10;25(11):1350-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma.
  • Systemic rituximab does not reduce the risk of CNS relapse or dissemination in patients with large cell lymphoma.
  • We therefore conducted a phase I dose-escalation study of intrathecal rituximab monotherapy in patients with recurrent CNS non-Hodgkin's lymphoma (NHL).
  • CONCLUSION: These results suggest that intrathecal rituximab (10 to 25 mg) is feasible and effective in NHL involving the CNS.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Central Nervous System Neoplasms / drug therapy. Eye Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Dose-Response Relationship, Drug. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Rituximab. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Oct 1;25(28):4508-9; author reply 4509-11 [17906219.001]
  • (PMID = 17312328.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR-00079; United States / NCI NIH HHS / CA / P50 CA097257; United States / NCI NIH HHS / CA / R01 CA101042-01
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


18. Badruddoja MA, Keir ST, King I, Zeidner J, Vredenburgh JJ, Muhlbaier LH, Bigner DD, Friedman HS: Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice. Neuro Oncol; 2007 Jul;9(3):240-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice.
  • The current study was designed to assess the activity of VNP40101M administered at a dose of 18 mg/kg daily for five days against a panel of human adult and pediatric CNS tumors growing subcutaneously or intracranially in athymic nude mice.
  • The results demonstrated statistically significant (p < 0.05) growth delays of 15.0, 8.3, 51.0, 60+, 60+, and 60+ days in subcutaneous xenografts derived from childhood glioblastoma multiforme (D-456 MG), childhood ependymoma (D-528 EP and D-612 EP), childhood medulloblastoma (D-425 MED), and adult malignant glioma (D-245 MG and D-54 MG), respectively, with corresponding tumor regressions in 10 of 10, 4 of 10, 8 of 10, 9 of 10, 9 of 10, and 10 of 10 treated mice, respectively.
  • Additional experiments conducted against subcutaneous D-245 MG xenografts by using reduced doses of 13.5 or 9.0 mg/kg daily for five days demonstrated tumor growth delays of 82.2 and 53.5 days, with corresponding tumor regressions in 8 of 9 and 9 of 10 treated mice, respectively (all values, p < 0.001), with one toxic death.
  • These findings suggest that VNP40101M is active in the treatment of a wide range of human central nervous system tumors and warrants translation to the clinic.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 1994;34(2):171-4 [8194169.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(14):5368-72 [2164681.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2853-7 [7796412.001]
  • [Cites] Cancer Res. 1997 Jul 15;57(14):2933-6 [9230204.001]
  • [Cites] Invest New Drugs. 2005 Mar;23(2):123-35 [15744588.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Biochem Pharmacol. 2000 Feb 1;59(3):283-91 [10609557.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3033-8 [11306484.001]
  • [Cites] Int J Toxicol. 2002 Jan-Feb;21(1):23-38 [11936896.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Apr;53(4):288-95 [14685775.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):2908-17 [15131024.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Neurosurgery. 1979 Apr;4(4):308-14 [450229.001]
  • [Cites] Cancer Res. 1988 Aug 1;48(15):4189-95 [3390813.001]
  • [Cites] J Neurooncol. 1994;20(2):111-20 [7807189.001]
  • (PMID = 17522334.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / P50 NS020023; United States / NINDS NIH HHS / NS / 5P50-NS20023-23
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hydrazines; 0 / Prodrugs; 0 / Sulfonamides; 14J2G0U3NQ / laromustine
  • [Other-IDs] NLM/ PMC1907418
  •  go-up   go-down


19. Kiewe P, Fischer L, Martus P, Thiel E, Korfel A: Meningeal dissemination in primary CNS lymphoma: diagnosis, treatment, and survival in a large monocenter cohort. Neuro Oncol; 2010 Apr;12(4):409-17
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningeal dissemination in primary CNS lymphoma: diagnosis, treatment, and survival in a large monocenter cohort.
  • The frequency of meningeal dissemination (MD) in primary CNS lymphoma (PCNSL), its prognostic impact, and optimal management have not been defined thus far.
  • [MeSH-major] Central Nervous System Neoplasms / mortality. Central Nervous System Neoplasms / pathology. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / pathology. Meningeal Neoplasms / mortality. Meningeal Neoplasms / secondary
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / therapy. Neoplasm Staging. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Neurol. 1995 Aug;38(2):202-9 [7654067.001]
  • [Cites] J Neurooncol. 2009 Feb;91(3):299-305 [18931887.001]
  • [Cites] Cancer. 1998 Feb 15;82(4):733-9 [9477107.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):864-71 [9508167.001]
  • [Cites] Am J Clin Pathol. 1998 Sep;110(3):341-6 [9728609.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3000-6 [9738568.001]
  • [Cites] Blood. 1999 Sep 1;94(5):1738-46 [10477699.001]
  • [Cites] Blood. 2005 Jan 15;105(2):496-502 [15358629.001]
  • [Cites] Br J Haematol. 2005 Jan;128(2):177-83 [15638851.001]
  • [Cites] Ann Oncol. 2005 Mar;16(3):445-9 [15653703.001]
  • [Cites] J Neurooncol. 2005 Apr;72(2):169-77 [15925998.001]
  • [Cites] Acta Oncol. 2005;44(7):728-34 [16227164.001]
  • [Cites] Haematologica. 2006 Mar;91(3):429-30 [16531273.001]
  • [Cites] J Neurol Sci. 2006 Aug 15;247(1):39-46 [16678210.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4570-4 [17008697.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5711-5 [17116938.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):237-9 [10563429.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):2077-86 [10595937.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):519-26 [10653867.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3144-50 [10963643.001]
  • [Cites] Br J Neurosurg. 2000 Aug;14(4):313-5; discussion 316 [11045195.001]
  • [Cites] Diagn Cytopathol. 2000 Dec;23(6):369-74 [11074639.001]
  • [Cites] Neurology. 2002 Feb 12;58(3):390-6 [11839837.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4643-8 [12488408.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):266-72 [12525518.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1044-9 [12637469.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2726-31 [12860951.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4483-8 [14597741.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4489-95 [14597744.001]
  • [Cites] Br J Haematol. 2004 Mar;124(6):762-8 [15009064.001]
  • [Cites] Neurology. 1979 Oct;29(10):1369-75 [573381.001]
  • [Cites] Blood. 1989 May 15;73(7):1942-50 [2713509.001]
  • [Cites] Ann Neurol. 1995 Jul;38(1):51-7 [7611725.001]
  • [Cites] Neurology. 2007 May 15;68(20):1674-9 [17502548.001]
  • [Cites] Cancer. 2008 Apr 15;112(8):1812-20 [18318432.001]
  • [Cites] Neurology. 2008 Sep 30;71(14):1102-8 [18824675.001]
  • [Cites] Br J Haematol. 1997 Oct;99(1):122-30 [9359512.001]
  • (PMID = 20308318.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2940610
  •  go-up   go-down


20. Yamanaka R, Shinbo Y, Sano M, Homma J, Tsuchiya N, Yajima N, Tamura T, Hondoh H, Takahashi H, Morii K, Onda K, Tanaka R: Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen. Leuk Lymphoma; 2007 Jun;48(6):1119-26
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen.
  • We report the efficacy of salvage therapy with a modified ProMACE-MOPP combined with radiation in patients with primary central nervous system lymphoma (PCNSL).
  • Nine patients with CNS relapse were retreated with additional cycles of the ProMACE-MOPP hybrid regimen with a 90% objective response rate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / radiotherapy. Lymphoma / drug therapy. Lymphoma / radiotherapy. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Salvage Therapy / methods
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Doxorubicin / analogs & derivatives. Doxorubicin / therapeutic use. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Humans. Male. Mechlorethamine / adverse effects. Mechlorethamine / therapeutic use. Methotrexate / adverse effects. Methotrexate / therapeutic use. Middle Aged. Neurotoxicity Syndromes / drug therapy. Neurotoxicity Syndromes / radiotherapy. Prednisone / adverse effects. Prednisone / therapeutic use. Procarbazine / adverse effects. Procarbazine / therapeutic use. Retrospective Studies. Survival Analysis. Vincristine / adverse effects. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577775.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; D58G680W0G / pirarubicin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ProMACE-MOPP protocol
  •  go-up   go-down


21. Maza S, Kiewe P, Munz DL, Korfel A, Hamm B, Jahnke K, Thiel E: First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma. Neuro Oncol; 2009 Aug;11(4):423-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma.
  • Most patients with primary CNS lymphoma (PCNSL) relapse after primary therapy.
  • Anti-CD20 immunotherapy has expanded treatment options in systemic B-cell lymphoma; however, its use is limited by reconstitution of the blood-brain barrier after tumor shrinkage.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Central Nervous System Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Radioimmunotherapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / radiotherapy. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Male. Middle Aged. Prognosis. Prospective Studies. Remission Induction. Survival Rate. Tissue Distribution. Yttrium Radioisotopes / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 1999 Jul;43(3):249-57 [10563431.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2453-63 [12011122.001]
  • [Cites] Blood. 2003 Jan 15;101(2):466-8 [12393404.001]
  • [Cites] Eur J Cancer. 1991;27(11):1356-61 [1835848.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1927-32 [9731049.001]
  • [Cites] Eur J Haematol. 2005 Apr;74(4):348-52 [15777348.001]
  • [Cites] Cancer. 2007 Dec 1;110(11):2528-34 [17932895.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1710-1 [15972281.001]
  • [Cites] J Neurooncol. 2006 Mar;77(1):53-8 [16283435.001]
  • [Cites] Clin Lymphoma Myeloma. 2006 Nov;7(3):236-8 [17229341.001]
  • [Cites] J Neurooncol. 2007 Jul;83(3):291-3 [17245621.001]
  • [Cites] Leuk Lymphoma. 2007 Sep;48(9):1712-20 [17786706.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5034-43 [15955902.001]
  • (PMID = 19060176.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan
  • [Other-IDs] NLM/ PMC2743222
  •  go-up   go-down


22. Daood M, Tsai C, Ahdab-Barmada M, Watchko JF: ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS. Neuropediatrics; 2008 Aug;39(4):211-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS.
  • Little is known about the neonatal and developmental expression of P-gp/ABCB1, MRP1/ABCC1, and BCRP/ABCG2 in the human central nervous system (CNS), therefore post-mortem CNS tissue from infants born at 22 (0/7)-42 (0/7) weeks of gestation and adults was immunostained to determine their ontogeny and cellular localization.
  • P-gp/ABCB1, MRP1/ABCC1 and BCRP/ABCG2 in adult brain matched term newborn CNS but with more intense immunostaining.
  • We conclude that P-gp/ABCB1, MRP1/ABCC1, and BCRP/ABCG2 are expressed in a developmental, cell specific, fashion in the human CNS.
  • The complementary pattern of P-gp/ABCB1 and BCRP/ABCG2 at the blood-brain with MRP1/ABCC1 at the blood-CSF barriers may limit CNS uptake and retention of drugs and toxins in neonates.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci Res. 2000 Jun 1;60(5):594-601 [10820430.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5269-77 [11016657.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1469-76 [11245453.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Nov 9;288(4):1064-8 [11689020.001]
  • [Cites] J Neural Transm Suppl. 2001;(61):35-45 [11771758.001]
  • [Cites] Biol Neonate. 2002 Jan;81(1):58-64 [11803178.001]
  • [Cites] J Perinatol. 2001 Dec;21 Suppl 1:S43-7; discussion S59-62 [11803416.001]
  • [Cites] Brain. 2002 Jan;125(Pt 1):22-31 [11834590.001]
  • [Cites] J Pathol. 2002 Oct;198(2):213-9 [12237881.001]
  • [Cites] Neuroreport. 2002 Nov 15;13(16):2059-63 [12438926.001]
  • [Cites] J Histochem Cytochem. 2002 Dec;50(12):1671-6 [12486090.001]
  • [Cites] Neuroscience. 2003;118(2):417-29 [12699778.001]
  • [Cites] Dev Growth Differ. 2003 Aug;45(4):377-87 [12950279.001]
  • [Cites] FASEB J. 2003 Nov;17(14):2085-7 [12958161.001]
  • [Cites] Neuroscience. 2004;123(3):751-9 [14706787.001]
  • [Cites] Pediatr Neurol. 2004 Feb;30(2):102-6 [14984901.001]
  • [Cites] Cell Mol Neurobiol. 2004 Feb;24(1):101-7 [15049514.001]
  • [Cites] Trends Mol Med. 2004 Feb;10(2):65-70 [15102359.001]
  • [Cites] Neuroscience. 2004;129(2):349-60 [15501592.001]
  • [Cites] J Neurochem. 1976 Aug;27(2):577-83 [966000.001]
  • [Cites] Differentiation. 1983;25(2):193-203 [6198232.001]
  • [Cites] J Neuropathol Exp Neurol. 1984 Jan;43(1):45-56 [6693927.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jan;86(2):695-8 [2563168.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jan;87(1):152-6 [1688652.001]
  • [Cites] Sel Cancer Ther. 1991 Summer;7(2):49-58 [1721722.001]
  • [Cites] Am J Pathol. 1992 Nov;141(5):1063-72 [1359789.001]
  • [Cites] Biochim Biophys Acta. 1993 Aug 15;1150(2):147-54 [8102251.001]
  • [Cites] Am J Pathol. 1994 Feb;144(2):227-36 [7508682.001]
  • [Cites] Am J Pathol. 1996 Apr;148(4):1237-47 [8644864.001]
  • [Cites] Vet Pathol. 1996 Sep;33(5):533-41 [8885180.001]
  • [Cites] Acta Neuropathol. 1997 May;93(5):450-60 [9144583.001]
  • [Cites] Histochem Cell Biol. 1997 Aug;108(2):179-82 [9272437.001]
  • [Cites] Biochem J. 1997 Sep 1;326 ( Pt 2):539-44 [9291129.001]
  • [Cites] Neuroimage. 1994 Nov;1(4):276-87 [9343577.001]
  • [Cites] J Neurochem. 1998 Mar;70(3):1151-9 [9489736.001]
  • [Cites] J Neurochem. 1998 Aug;71(2):705-15 [9681461.001]
  • [Cites] Pediatr Res. 1998 Nov;44(5):763-6 [9803459.001]
  • [Cites] Brain Res. 1999 Feb 20;819(1-2):143-6 [10082869.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3900-5 [10097135.001]
  • [Cites] J Neurobiol. 1999 Jun 5;39(3):383-92 [10363911.001]
  • [Cites] Toxicol Appl Pharmacol. 2005 May 1;204(3):216-37 [15845415.001]
  • [Cites] Epilepsia. 2005 Jun;46(6):849-57 [15946326.001]
  • [Cites] Neuropathol Appl Neurobiol. 2006 Feb;32(1):51-63 [16409553.001]
  • [Cites] Drug Metab Dispos. 2006 Feb;34(2):288-95 [16303871.001]
  • [Cites] J Histochem Cytochem. 2006 Oct;54(10):1159-67 [16801529.001]
  • [Cites] J Neurol Sci. 2007 Jul 15;258(1-2):84-92 [17459414.001]
  • [Cites] Seizure. 2007 Sep;16(6):493-503 [17482840.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Jan;67(1):50-61 [18091560.001]
  • (PMID = 19165709.001).
  • [ISSN] 0174-304X
  • [Journal-full-title] Neuropediatrics
  • [ISO-abbreviation] Neuropediatrics
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS038993-07; United States / NINDS NIH HHS / NS / NS 38993; United States / NINDS NIH HHS / NS / R01 NS038993-07; United States / NINDS NIH HHS / NS / R01 NS038993-08; United States / NINDS NIH HHS / NS / NS038993-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / ABCG2 protein, human; 0 / Multidrug Resistance-Associated Proteins; 0 / Neoplasm Proteins; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / multidrug resistance-associated protein 1
  • [Other-IDs] NLM/ NIHMS174607; NLM/ PMC2821654
  •  go-up   go-down


23. Salzburg J, Burkhardt B, Zimmermann M, Wachowski O, Woessmann W, Oschlies I, Klapper W, Wacker HH, Ludwig WD, Niggli F, Mann G, Gadner H, Riehm H, Schrappe M, Reiter A: Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report. J Clin Oncol; 2007 Sep 1;25(25):3915-22
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report.
  • PURPOSE: We analyzed the prevalence, clinical pattern, and prognostic impact of CNS involvement in a large cohort of children and adolescents diagnosed with non-Hodgkin's lymphoma (NHL), with special attention to differences according to NHL subtype.
  • RESULTS: CNS involvement was diagnosed in 141 (5.9%) of 2,381 patients and was associated with an advanced stage of NHL.
  • The percentage of CNS-positive patients was 8.8% for Burkitt's lymphoma/Burkitt's leukemia (BL/B-ALL), 5.4% for precursor B-lymphoblastic lymphoma (pB-LBL), 3.3% for anaplastic large-cell lymphoma, 3.2% for T-cell-LBL, 2.6% for diffuse large B-cell lymphoma, and 0% for primary mediastinal large B-cell NHL (P < .001).
  • Most CNS-positive patients with pB-LBL, T-LBL, or BL/B-ALL had meningeal disease.
  • For the 112 CNS-positive patients, pEFS was 64% +/- 5%, compared with 86% +/- 1% for the 1,927 CNS-negative patients (P < .001).
  • Although CNS disease had no impact on pEFS for advanced-stage T-LBL patients, CNS-positive patients with BL/B-ALL had a worse average outcome than CNS-negative patients with stage IV BL/B-ALL (60% +/- 5% v 81% +/- 3%; P < .001).
  • In multivariate analysis, CNS disease was the strongest predictor for relapse in BL/B-ALL patients with advanced-stage disease.
  • CONCLUSION: Six percent of childhood/adolescent NHL patients were CNS positive.
  • However, the prevalence, pattern, and prognostic impact of CNS involvement differed among NHL subtypes.
  • [MeSH-major] Brain Neoplasms / epidemiology. Head and Neck Neoplasms / epidemiology. Lymphoma, Non-Hodgkin / classification. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Epidural Neoplasms / epidemiology. Epidural Neoplasms / therapy. Female. Germany / epidemiology. Humans. Infant. Infant, Newborn. Male. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Prevalence. Prognosis. Treatment Failure. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17761975.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


24. Ruppert AM, Beau-Faller M, Neuville A, Guerin E, Voegeli AC, Mennecier B, Legrain M, Molard A, Jeung MY, Gaub MP, Oudet P, Quoix E: EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up. Eur Respir J; 2009 Feb;33(2):436-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.
  • However, after an initial response, most patients will recur, particularly within the central nervous system.
  • Persistent cerebral tyrosine kinase inhibitor sensitivity should be considered in patients presenting with an early central nervous system relapse after stopping epidermal growth factor receptor tyrosine kinase inhibitor, even with a T790M-resistant mutation in noncerebral metastases.
  • Questions remain concerning the selection of sub-clones during epidermal growth factor receptor tyrosine kinase inhibitor therapy, which could differ according to metastatic sites, especially in the central nervous system.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Central Nervous System Neoplasms / secondary. Central Nervous System Neoplasms / therapy. Lung Neoplasms / pathology. Lung Neoplasms / therapy. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm. Erlotinib Hydrochloride. Humans. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Male. Neoplasm Metastasis. Quinazolines / administration & dosage. Recurrence. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19181917.001).
  • [ISSN] 1399-3003
  • [Journal-full-title] The European respiratory journal
  • [ISO-abbreviation] Eur. Respir. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


25. Fischer L, Thiel E, Klasen HA, Birkmann J, Jahnke K, Martus P, Korfel A: Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol; 2006 Jul;17(7):1141-5
Hazardous Substances Data Bank. Topotecan .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective trial on topotecan salvage therapy in primary CNS lymphoma.
  • BACKGROUND: Standard salvage therapy has not been established for recurrent primary central nervous system lymphoma (PCNSL).

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16603598.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7M7YKX2N15 / Topotecan
  •  go-up   go-down


26. Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, Goss B, Ford J: CNS germ cell tumors: pattern of failure and effects of radiation volume. J Med Assoc Thai; 2006 Apr;89(4):415-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS germ cell tumors: pattern of failure and effects of radiation volume.
  • This retrospective study was conducted to evaluate local control and overall survival after radiotherapy for patients with intracranial germ cell tumors and to investigate the influence of irradiated field on treatment outcome.
  • Thirty-two patients with surgically confirmed or suspected primary intracranial germ cell tumors (GCT) treated at the Division of Therapeutic Radiology and Oncology, Chiang Mai University, Chiang Mai, Thailand between January 1988 and December 1999 were reviewed Seven patients were not included in the analysis of treatment outcome and survival due to incompleteness of radiation treatment or death before the end of treatment.
  • Patients were irradiated to the primary tumor with an adequate margin in 7 patients, to the whole brain with a cone down boost in 8 patients.
  • [MeSH-major] Central Nervous System Neoplasms / radiotherapy. Neoplasm Recurrence, Local. Neoplasms, Germ Cell and Embryonal / radiotherapy. Treatment Outcome
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Male. Middle Aged. Pinealoma / mortality. Pinealoma / radiotherapy. Retrospective Studies. Risk Factors. Survival Rate. Thailand / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16696383.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


27. Lotze C, Schüler F, Krüger WH, Hirt C, Kirsch M, Vogelgesang S, Schmidt CA, Dölken G: Combined immunoradiotherapy induces long-term remission of CNS relapse of peripheral, diffuse, large-cell lymphoma after allogeneic stem cell transplantation: case study. Neuro Oncol; 2005 Oct;7(4):508-10
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined immunoradiotherapy induces long-term remission of CNS relapse of peripheral, diffuse, large-cell lymphoma after allogeneic stem cell transplantation: case study.
  • Relapse of peripheral non-Hodgkin's lymphoma (NHL) in the central nervous system commonly has a poor prognosis.
  • On day +83 after transplantation a CNS relapse of the lymphoma occurred.
  • [MeSH-major] Antibodies / therapeutic use. Brain Neoplasms / radiotherapy. Graft vs Leukemia Effect / physiology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Antigens, CD20 / immunology. Humans. Male. Neoplasm Recurrence, Local / immunology. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Cancer Res. 2001;82:133-85 [11447762.001]
  • [Cites] Bone Marrow Transplant. 2003 Oct;32(8):843-6 [14520432.001]
  • [Cites] Blood. 2004 Jan 15;103(2):725-31 [12947008.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2208-16 [10498590.001]
  • [Cites] Bone Marrow Transplant. 1997 Sep;20(6):503-6 [9313885.001]
  • [Cites] Blood. 1998 Feb 15;91(4):1178-84 [9454747.001]
  • [Cites] Leuk Lymphoma. 1999 Jun;34(1-2):185-90 [10350348.001]
  • [Cites] Blood. 1990 Dec 15;76(12):2462-5 [2265242.001]
  • (PMID = 16212815.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, CD20
  • [Other-IDs] NLM/ PMC1871735
  •  go-up   go-down


28. Neuhaus T, Ko Y, Muller RP, Grabenbauer GG, Hedde JP, Schueller H, Kocher M, Stier S, Fietkau R: A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer. Br J Cancer; 2009 Jan 27;100(2):291-7
Hazardous Substances Data Bank. Topotecan .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer.
  • A total of 320 patients with CNS-metastases due to SCLC or NSCLC were projected.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / therapy. Carcinoma, Non-Small-Cell Lung / therapy. Cranial Irradiation. Lung Neoplasms / therapy. Small Cell Lung Carcinoma / therapy. Topotecan / therapeutic use
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Quality of Life. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiat Oncol. 2006;1:20 [16808850.001]
  • [Cites] Radiat Oncol. 2006;1:19 [16800900.001]
  • [Cites] Front Radiat Ther Oncol. 1999;33:354-63 [10549507.001]
  • [Cites] J Clin Oncol. 2000 Oct 1;18(19):3400-8 [11013281.001]
  • [Cites] Ann Oncol. 2001 Jan;12(1):59-67 [11249050.001]
  • [Cites] Forum (Genova). 2001 Jan-Mar;11(1):4-26 [11734861.001]
  • [Cites] Eur J Cancer. 2002 Feb;38(3):367-74 [11818201.001]
  • [Cites] Eur J Cancer. 2002 Sep;38(13):1724-9 [12175688.001]
  • [Cites] J Clin Oncol. 2002 Sep 1;20(17):3644-50 [12202665.001]
  • [Cites] Melanoma Res. 2003 Feb;13(1):97-103 [12569292.001]
  • [Cites] Neurol Clin. 2003 Feb;21(1):1-23, vii [12690643.001]
  • [Cites] Oncologist. 2004;9(1):68-79 [14755016.001]
  • [Cites] J Neurosurg. 2004 May;100(5):842-7 [15137603.001]
  • [Cites] Lancet. 2004 May 22;363(9422):1665-72 [15158627.001]
  • [Cites] Lung Cancer. 2004 Oct;46(1):107-11 [15364138.001]
  • [Cites] Br J Cancer. 1978 Dec;38(6):757-66 [369589.001]
  • [Cites] Biometrics. 1979 Sep;35(3):549-56 [497341.001]
  • [Cites] Neurosurgery. 1991 Feb;28(2):201-5 [1997887.001]
  • [Cites] N Engl J Med. 1990 Feb 22;322(8):494-500 [2405271.001]
  • [Cites] Cancer. 1981 Jul 15;48(2):384-94 [7237407.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(3):515-8 [1310495.001]
  • [Cites] Cancer Res. 1994 Oct 1;54(19):5118-22 [7923128.001]
  • [Cites] Cancer Chemother Pharmacol. 1996;37(3):195-202 [8529278.001]
  • [Cites] J Neurooncol. 1996 Oct;30(1):1-6 [8864997.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2090-6 [9164222.001]
  • [Cites] Ann Med. 1998 Jun;30(3):296-9 [9677016.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):658-67 [10080612.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):795-803 [10098435.001]
  • [Cites] Oncologist. 2004;9 Suppl 6:43-52 [15616149.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):185-91 [15629610.001]
  • [Cites] Strahlenther Onkol. 2005 Jan;181(1):20-5 [15660189.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(3):CD003869 [16856022.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):839-44 [17379446.001]
  • (PMID = 19127261.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7M7YKX2N15 / Topotecan
  • [Other-IDs] NLM/ PMC2634726
  •  go-up   go-down


29. Cooper PB, Auerbach A, Aguilera NS, Adair C, Moores L, Geyer D, Rushing EJ: Rare primary CNS anaplastic large cell lymphoma in an immunocompetent adult: a clinical-pathologic case report and review case of the literature. Clin Neuropathol; 2006 Sep-Oct;25(5):232-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare primary CNS anaplastic large cell lymphoma in an immunocompetent adult: a clinical-pathologic case report and review case of the literature.
  • OBJECTIVE AND IMPORTANCE: Isolated anaplastic large cell lymphoma (ALCL) presenting in the primary central nervous system is distinctly uncommon.
  • The authors describe a case that clinically and radiographically simulated a primary glial neoplasm.
  • There appeared to be a clear demarcation between white matter and tumor with no obvious necrosis.
  • CONCLUSION: Reported in less than 20 patients, primary ALCL in an immunocompetent patient is rarely found intracranially; however, its ability to mimic glial neoplasms as well as other pathologies underlines its importance.
  • [MeSH-major] Brain Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biomarkers, Tumor / analysis. Combined Modality Therapy. Diagnosis, Differential. Glioma / pathology. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Radiotherapy. Seizures / etiology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Neuropathol. 2007 Jan-Feb;26(1):39-40; author reply 40 [17290938.001]
  • (PMID = 17007446.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


30. Pettorini BL, Narducci A, de Carlo A, Abet F, Caldarelli M, Massimi L, Tamburrini G, Di Rocco C: Thyroid neoplasm after central nervous system irradiation for medulloblastoma in childhood: report of two cases. Childs Nerv Syst; 2009 May;25(5):631-4
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid neoplasm after central nervous system irradiation for medulloblastoma in childhood: report of two cases.
  • However, only a few papers on radioinduced thyroid neoplasms after CNS irradiation have been published in the literature.
  • We report on two additional cases of thyroid neoplasms following childhood CNS irradiation for the treatment of a posterior fossa medulloblastoma.
  • [MeSH-major] Carcinoma, Papillary / etiology. Cerebellar Neoplasms / radiotherapy. Cranial Irradiation / adverse effects. Medulloblastoma / radiotherapy. Neoplasms, Radiation-Induced / etiology. Thyroid Neoplasms / etiology
  • [MeSH-minor] Female. Humans. Magnetic Resonance Imaging. Young Adult

  • Genetic Alliance. consumer health - Medulloblastoma.
  • Genetic Alliance. consumer health - Medulloblastoma, childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19225785.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


31. Yamanaka R, Morii K, Shinbo Y, Homma J, Sano M, Tsuchiya N, Yajima N, Tamura T, Hondoh H, Takahashi H, Kakuma T, Tanaka R: Results of treatment of 112 cases of primary CNS lymphoma. Jpn J Clin Oncol; 2008 May;38(5):373-80
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of treatment of 112 cases of primary CNS lymphoma.
  • BACKGROUND: Chemotherapy with or without radiotherapy is the mainstay of treatment for primary central nervous system lymphoma (PCNSL).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / radiotherapy. Cranial Irradiation. Lymphoma / drug therapy. Lymphoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cognition / drug effects. Cognition / radiation effects. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Kaplan-Meier Estimate. Karnofsky Performance Status. Leucovorin / administration & dosage. Male. Mechlorethamine / administration & dosage. Methotrexate / administration & dosage. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Procarbazine / administration & dosage. Radiotherapy, Adjuvant. Retrospective Studies. Salvage Therapy / methods. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18413337.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; MOPP protocol; PROMACE protocol
  •  go-up   go-down


32. MacFadyen J, Savage K, Wienke D, Isacke CM: Endosialin is expressed on stromal fibroblasts and CNS pericytes in mouse embryos and is downregulated during development. Gene Expr Patterns; 2007 Jan;7(3):363-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endosialin is expressed on stromal fibroblasts and CNS pericytes in mouse embryos and is downregulated during development.
  • Finally, the fibroblast and pericyte expression of endosialin changes dynamically during development and becomes highly restricted in adult mouse tissues.
  • [MeSH-major] Antigens, CD / genetics. Central Nervous System / blood supply. Down-Regulation. Fibroblasts / metabolism. Gene Expression Regulation, Developmental. Neoplasm Proteins / genetics. Pericytes / metabolism


33. Ogino H, Shibamoto Y, Takanaka T, Suzuki K, Ishihara S, Yamada T, Sugie C, Nomoto Y, Mimura M: CNS germinoma with elevated serum human chorionic gonadotropin level: clinical characteristics and treatment outcome. Int J Radiat Oncol Biol Phys; 2005 Jul 1;62(3):803-8
Genetic Alliance. consumer health - Germinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS germinoma with elevated serum human chorionic gonadotropin level: clinical characteristics and treatment outcome.
  • PURPOSE: The prognostic significance of human chorionic gonadotropin (HCG) level in central nervous system germinoma remains controversial.
  • METHODS AND MATERIALS: We undertook a multi-institutional retrospective analysis of 103 patients with central nervous system germinoma whose serum HCG and/or beta-HCG level had been measured before treatment between 1984 and 2002.
  • The proportion of HCG-producing tumors was higher in the lesions at the basal ganglia than in the lesions at the other sites.
  • No correlation was found between tumor size and HCG level, but there seemed to be a weak correlation between size and beta-HCG.
  • Also, no other patient-, tumor-, or treatment-related factors seemed to influence the prognosis of the patients.
  • Relationship between tumor size and site and HCG level should be investigated further.
  • [MeSH-major] Central Nervous System Neoplasms / blood. Chorionic Gonadotropin / blood. Germinoma / blood. Neoplasm Proteins / blood
  • [MeSH-minor] Adolescent. Adult. Chorionic Gonadotropin, beta Subunit, Human / blood. Female. Humans. Male. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15936563.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / Neoplasm Proteins
  •  go-up   go-down


34. Sheedy SP, Welker KM, DeLone DR, Gilbertson JR: CNS metastases of carcinoma ex pleomorphic adenoma of the parotid gland. AJNR Am J Neuroradiol; 2006 Aug;27(7):1483-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS metastases of carcinoma ex pleomorphic adenoma of the parotid gland.
  • Pleomorphic adenomas (PAs), also known as benign mixed tumors, are common tumors of the parotid gland.
  • These tumors occasionally undergo malignant transformation, with potentially devastating consequences.
  • [MeSH-major] Adenocarcinoma / secondary. Adenoma, Pleomorphic / pathology. Brain Neoplasms / secondary. Neoplasms, Multiple Primary / pathology. Parotid Neoplasms / pathology. Spinal Cord Neoplasms / secondary
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / pathology. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16908563.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Zhang D, Hu LB, Henning TD, Ravarani EM, Zou LG, Feng XY, Wang WX, Wen L: MRI findings of primary CNS lymphoma in 26 immunocompetent patients. Korean J Radiol; 2010 May-Jun;11(3):269-77
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI findings of primary CNS lymphoma in 26 immunocompetent patients.
  • OBJECTIVE: To record the MR imaging features of primary central nervous system lymphoma (PCNSL) and compare these features in monofocal and multifocal disease.
  • Tumor location, tumor size, signal intensity, enhancement characteristics, age distribution, peritumoral edema, cystic changes, and the presence of calcifications were assessed.
  • Tumor size differed significantly between the two groups (t = 3.129, p < 0.01) and mildly or moderately enhanced lesions were more frequently found in the monofocal group (p < 0.05).
  • Monofocal PCNSL cases typically have larger sized tumors with mild or moderate enhancement.
  • [MeSH-major] Brain / pathology. Brain Neoplasms / pathology. Immunocompetence. Lymphoma / pathology. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Contrast Media. Female. Gadolinium DTPA. Humans. Image Enhancement / methods. Male. Middle Aged. Observer Variation. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Tumor Pathol. 1999;16(1):29-35 [10532421.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):199-201 [10563423.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):219-26 [10563426.001]
  • [Cites] Neuroradiology. 1999 Nov;41(11):820-5 [10602854.001]
  • [Cites] Neurology. 2000 Apr 11;54(7):1427-33 [10751251.001]
  • [Cites] Neuroradiology. 2000 Oct;42(10):738-41 [11110076.001]
  • [Cites] AJR Am J Roentgenol. 2001 May;176(5):1319-26 [11312202.001]
  • [Cites] Eur Radiol. 2002 Feb;12(2):329-40 [11870430.001]
  • [Cites] Clin Neurol Neurosurg. 2003 Apr;105(2):78-86 [12691795.001]
  • [Cites] Clin Radiol. 1982 May 3;33(3):331-6 [7075140.001]
  • [Cites] Neuroradiology. 1984;26(6):485-92 [6504318.001]
  • [Cites] AJR Am J Roentgenol. 1986 Feb;146(2):271-6 [3484575.001]
  • [Cites] J Neurosurg. 1986 Nov;65(5):592-9 [3772444.001]
  • [Cites] Radiology. 1988 Apr;167(1):211-5 [3279454.001]
  • [Cites] J Neurosurg. 1988 Jun;68(6):835-53 [3286832.001]
  • [Cites] Neuroradiology. 1992;34(1):36-42 [1553036.001]
  • [Cites] Ann Neurol. 1993 Mar;33(3):308-11 [8498814.001]
  • [Cites] Cancer. 1994 Aug 15;74(4):1383-97 [8055462.001]
  • [Cites] Clin Radiol. 1994 Oct;49(10):696-702 [7955832.001]
  • [Cites] Radiology. 1995 Jan;194(1):271-6 [7997566.001]
  • [Cites] J Neurosurg. 1995 Jan;82(1):77-82 [7815138.001]
  • [Cites] AJR Am J Roentgenol. 1995 Sep;165(3):626 [7645482.001]
  • [Cites] Neuroradiology. 1996 Jan;38(1):34-7 [8773272.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Mar;18(3):563-72 [9090424.001]
  • [Cites] Ann Oncol. 1997 Mar;8(3):227-34 [9137790.001]
  • [Cites] Radiographics. 1997 Nov-Dec;17(6):1497-526 [9397461.001]
  • [Cites] Clin Radiol. 1998 Jun;53(6):428-34 [9651058.001]
  • [Cites] Neurochirurgie. 1997;43(6):385-7 [9706618.001]
  • [Cites] Clin Neurol Neurosurg. 2004 Dec;107(1):55-63 [15567554.001]
  • [Cites] AJR Am J Roentgenol. 2005 May;184(5):1679-85 [15855138.001]
  • [Cites] J Neurooncol. 2005 Apr;72(2):169-77 [15925998.001]
  • [CommentIn] Korean J Radiol. 2010 Nov-Dec;11(6):702-3 [21076600.001]
  • (PMID = 20461180.001).
  • [ISSN] 2005-8330
  • [Journal-full-title] Korean journal of radiology
  • [ISO-abbreviation] Korean J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  • [Other-IDs] NLM/ PMC2864853
  • [Keywords] NOTNLM ; Brain neoplasm / Computed tomography (CT) / Lymphoma / Magnetic resonance (MR)
  •  go-up   go-down


36. Giebel S, Krawczyk-Kuliś M, Adamczyk-Cioch M, Czyz A, Lech-Marańda E, Piatkowska-Jakubas B, Paluszewska M, Pałynyczko G, Piszcz J, Hołowiecki J, Polish Adult Leukemia Group: Prophylaxis and therapy of central nervous system involvement in adult acute lymphoblastic leukemia: recommendations of the Polish Adult Leukemia Group. Pol Arch Med Wewn; 2008 Jun;118(6):356-61
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prophylaxis and therapy of central nervous system involvement in adult acute lymphoblastic leukemia: recommendations of the Polish Adult Leukemia Group.
  • The central nervous system (CNS) is one of the most frequent extramedullary locations of adult acute lymphoblastic leukemia (ALL), affecting approximately 5% of patients at diagnosis.
  • In case of relapse, if no prophylaxis was administered, the rate of CNS involvement reaches 30-50%.
  • As the prognosis of patients with isolated or mixed CNS relapse is particularly poor, adequate prophylaxis seems critical.
  • The treatment comprises intrathecal cytostatics, cranial and spinal cord irradiation, as well as systemic chemotherapy including agents penetrating to the CNS.
  • This strategy allows a reduction in CNS relapses to less than 5% of cases.
  • Compliance to the prophylactic protocols should be one of the principles in the treatment of adult ALL.
  • [MeSH-major] Central Nervous System Neoplasms / prevention & control. Central Nervous System Neoplasms / therapy. Neoplasm Recurrence, Local. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Quality of Life

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18619191.001).
  • [Journal-full-title] Polskie Archiwum Medycyny Wewnetrznej
  • [ISO-abbreviation] Pol. Arch. Med. Wewn.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 28
  •  go-up   go-down


37. Wolf RL, Wang J, Wang S, Melhem ER, O'Rourke DM, Judy KD, Detre JA: Grading of CNS neoplasms using continuous arterial spin labeled perfusion MR imaging at 3 Tesla. J Magn Reson Imaging; 2005 Oct;22(4):475-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Grading of CNS neoplasms using continuous arterial spin labeled perfusion MR imaging at 3 Tesla.
  • MATERIALS AND METHODS: CASL perfusion images were obtained preoperatively in 26 patients with brain neoplasms (19 high-grade gliomas (HGGs; WHO grades 3 and 4) and seven low-grade gliomas (LGGs; WHO grades 1 and 2)).
  • The mean and maximum tumor blood flow (TBF and TBFmax) were calculated in the neoplasm, including surrounding infiltrating tumor vs. edema.
  • [MeSH-major] Brain Neoplasms / diagnosis. Glioma / diagnosis. Magnetic Resonance Angiography / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Image Processing, Computer-Assisted. Male. Middle Aged. Spin Labels

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16161080.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / K23 NS43381; United States / NINDS NIH HHS / NS / NS045839; United States / NCRR NIH HHS / RR / RR002305
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Spin Labels
  •  go-up   go-down


38. Gutenberg A, Schulten HJ, Gunawan B, Ludwig HC, Brück W, Larsen J, Rohde V: CNS tumor 22 years after spinal neuroblastoma IV: diagnostic dilemma between recurrence and secondary malignancy. Pediatr Neurosurg; 2009;45(1):61-8
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS tumor 22 years after spinal neuroblastoma IV: diagnostic dilemma between recurrence and secondary malignancy.
  • We present the very unusual case of a young woman suffering from a brain tumor 22 years after a stage IV spinal neuroblastoma as an infant, demonstrating the difficulties of differentiating late neuroblastoma relapse from secondary supratentorial primitive neuroectodermal tumor (sPNET).
  • Lacking specific immunohistochemical features, the first cerebral tumor at the age of 21 was regarded as sPNET, and we pursued a therapeutic approach consisting of neurosurgical resection as well as irradiation and high-dose alkylator-based chemotherapy according to the HIT2000 protocol.
  • Moreover, the lack of PNET-specific translocations (EWS/FLI1 gene fusion) in both brain tumors as well as the development of hepatic metastases was more compatible with the diagnosis of a very late relapse 22 years after initial stage IV spinal neuroblastoma.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neoplasms, Second Primary / pathology. Neuroblastoma / pathology. Spinal Neoplasms / pathology
  • [MeSH-minor] Adult. DNA, Neoplasm / genetics. Diagnosis, Differential. Female. Genetic Markers. Humans. Immunohistochemistry. Infant. Magnetic Resonance Imaging. Neoplasm Staging. Time Factors

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19258732.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Genetic Markers
  •  go-up   go-down


39. Rezanko T, Tunakan M, Kahraman A, Sucu HK, Gelal F, Akkol I: Primary rhabdoid tumor of the brain in an adult. Neuropathology; 2006 Feb;26(1):57-61
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary rhabdoid tumor of the brain in an adult.
  • Rhabdoid tumor (RT) is an uncommon childhood neoplasm that typically arises within the kidney.
  • Since its description in 1978, several cases of primary extrarenal RT, including a CNS localization, have been reported.
  • The first case in the CNS was reported in 1985 and was defined as "rhabdoid tumor" initially, and was classified as grade IV in the most recent classification of the World Health Organization under the term of "atypical teratoid/rhabdoid tumor".
  • Nearly 200 cases of atypical teratoid/rhabdoid tumor of the CNS have been reported to date, most of them occurring in childhood.
  • This tumor, which was composed purely of rhabdoid cells with no additional primitive neuroectodermal, epithelial and mesenchymal components, was in a 27-year-old male patient.
  • In conclusion, RT should be considered also in the differential diagnosis of intracerebral neoplasms of adult patients.
  • [MeSH-major] Brain Neoplasms / pathology. Rhabdoid Tumor / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Meningioma / pathology

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • Genetic Alliance. consumer health - Brain Tumor, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16521480.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


40. Frobisher C, Lancashire ER, Winter DL, Jenkinson HC, Hawkins MM, British Childhood Cancer Survivor Study: Long-term population-based marriage rates among adult survivors of childhood cancer in Britain. Int J Cancer; 2007 Aug 15;121(4):846-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term population-based marriage rates among adult survivors of childhood cancer in Britain.
  • The objectives of this study were to assess the number of adult survivors of childhood cancer who ever married and the factors influencing marriage, compare observed marriages to those expected from the general population, and assess age at marriage and influencing factors.
  • Survivors with the following characteristics: males, CNS neoplasm, received radiotherapy, diagnosed with mental retardation, registered blind, low social functioning score (calculated from SF-36 health status measure), and achieved the highest level of educational attainment, were less likely to have married than the complementary survivor groups.
  • The largest ever married deficits were among male CNS neoplasm survivors aged 30 years or over (29-38%).
  • [MeSH-major] Marital Status. Neoplasms / epidemiology. Survivors
  • [MeSH-minor] Adolescent. Adult. Age of Onset. Child. Child, Preschool. Female. Follow-Up Studies. Great Britain. Health Status. Humans. Infant. Male. Middle Aged

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17450524.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


41. Evens AM, Ziegler SL, Gupta R, Augustyniak C, Gordon LI, Mehta J: Sustained hematologic and central nervous system remission with single-agent denileukin diftitox in refractory adult T-cell leukemia/lymphoma. Clin Lymphoma Myeloma; 2007 Jul;7(7):472-4
Hazardous Substances Data Bank. ZIDOVUDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained hematologic and central nervous system remission with single-agent denileukin diftitox in refractory adult T-cell leukemia/lymphoma.
  • Human T-lymphotrophic virus-1-associated adult T-cell leukemia/lymphoma (ATLL) is a rare and often fatal disease.
  • This study reports on a 55-year-old man with relapsed/refractory leukemic-phase ATLL including significant central nervous system (CNS) disease with resistance to previous zidovudine/IFN and arsenic trioxide/IFN treatment.
  • The patient experienced a rapid hematologic and CNS clinical response with single-agent denileukin diftitox therapy (18 microg/kg per day for 5 days).
  • He tolerated 8 cycles of denileukin diftitox therapy well and experienced a sustained complete hematologic and CNS remission.
  • [MeSH-major] Bone Marrow Transplantation. Central Nervous System Neoplasms / therapy. Diphtheria Toxin / administration & dosage. Hematologic Neoplasms / therapy. Interleukin-2 / administration & dosage. Leukemia-Lymphoma, Adult T-Cell / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Arsenicals / administration & dosage. Drug Resistance, Neoplasm / drug effects. Humans. Interferons / administration & dosage. Male. Middle Aged. Oxides / administration & dosage. Recombinant Fusion Proteins / administration & dosage. Recurrence. Remission Induction. Transplantation, Homologous. Zidovudine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875237.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Diphtheria Toxin; 0 / Interleukin-2; 0 / Oxides; 0 / Recombinant Fusion Proteins; 25E79B5CTM / denileukin diftitox; 4B9XT59T7S / Zidovudine; 9008-11-1 / Interferons; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


42. Frobisher C, Winter DL, Lancashire ER, Reulen RC, Taylor AJ, Eiser C, Stevens MC, Hawkins MM, British Childhood Cancer Survivor Study: Extent of smoking and age at initiation of smoking among adult survivors of childhood cancer in Britain. J Natl Cancer Inst; 2008 Aug 6;100(15):1068-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extent of smoking and age at initiation of smoking among adult survivors of childhood cancer in Britain.
  • We examined the extent of cigarette smoking, factors associated with being a current smoker, and age at initiation of regular smoking among adult survivors of childhood cancer and compared the survivors' smoking habits with those of the general population.
  • Current regular smoking was more prevalent among survivors of Wilms tumor or Hodgkin lymphoma than survivors of a central nervous system (CNS) neoplasm; in those aged 10-14 years at diagnosis than 0-4 years; in those not treated with radiotherapy; in those in manual occupations; in those who were separated, widowed, or divorced; in those with lower educational attainment; and in those not currently on long-term regular hospital follow-up.
  • CONCLUSION: The prevalence of smoking varies by subgroup among adult survivors of childhood cancer in the BCCSS but is substantially less overall than that in the general population.
  • [MeSH-major] Neoplasms / complications. Neoplasms / epidemiology. Smoking / epidemiology. Survivors / statistics & numerical data
  • [MeSH-minor] Actuarial Analysis. Adolescent. Adult. Age of Onset. Analysis of Variance. Child. Child, Preschool. Educational Status. Female. Great Britain / epidemiology. Humans. Linear Models. Logistic Models. Male. Odds Ratio. Prevalence. Proportional Hazards Models. Research Design. Risk Factors. Smoking Cessation. Socioeconomic Factors. Surveys and Questionnaires

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Smoking.
  • MedlinePlus Health Information. consumer health - Smoking and Youth.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2008 Aug 6;100(15):1048-9 [18664648.001]
  • (PMID = 18664655.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


43. Weingart J, Grossman SA, Carson KA, Fisher JD, Delaney SM, Rosenblum ML, Olivi A, Judy K, Tatter SB, Dolan ME: Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol; 2007 Feb 1;25(4):399-404
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.
  • PURPOSE: This phase I trial was designed to (1) establish the dose of O6-benzylguanine (O6-BG) administered intravenously as a continuous infusion that suppresses O6-alkylguanine-DNA alkyltransferase (AGT) levels in brain tumors, (2) evaluate the safety of extending continuous-infusion O6-BG at the optimal dose with intracranially implanted carmustine wafers, and (3) measure the pharmacokinetics of O6-BG and its metabolite.
  • Tumor samples were evaluated for AGT levels.
  • Future trials are required to determine if the inhibition of tumor AGT levels results in increased efficacy.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3025-31 [10955780.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3570-5 [9817277.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7178-87 [16192602.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6307-10 [11103789.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2277-83 [11980998.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1845-9 [12721262.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):28-32 [14769137.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):1871-4 [15041700.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(14):5368-72 [2164681.001]
  • [Cites] Cancer Commun. 1990;2(11):371-7 [2242301.001]
  • [Cites] J Neurosurg. 1991 Mar;74(3):441-6 [1993909.001]
  • [Cites] Cancer Res. 1991 Jul 1;51(13):3367-72 [1647266.001]
  • [Cites] J Neurosurg. 1992 Apr;76(4):640-7 [1545259.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;32(6):471-6 [8258196.001]
  • [Cites] Cancer Res. 1994 Oct 1;54(19):5123-30 [7923129.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 1995;51:167-223 [7659775.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):783-8 [8631014.001]
  • [Cites] Br J Cancer. 1996 Oct;74(7):1030-6 [8855970.001]
  • [Cites] Neurosurgery. 1997 Jul;41(1):44-8; discussion 48-9 [9218294.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1803-10 [9586894.001]
  • [Cites] J Clin Oncol. 2000 Oct 15;18(20):3522-8 [11032594.001]
  • (PMID = 17264335.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA14599; United States / NCI NIH HHS / CA / P30 CA014599; United States / NCI NIH HHS / CA / U01 CA062475; United States / NCRR NIH HHS / RR / M01 RR000055; United States / NCI NIH HHS / CA / U01 CA069852-12; United States / NCRR NIH HHS / RR / M01 RR000055-400764; United States / NCI NIH HHS / CA / CA69852; United States / NCRR NIH HHS / RR / RR000055-400764; United States / NCI NIH HHS / CA / CA069852-12; United States / NCI NIH HHS / CA / P30 CA014599-289015; United States / NCI NIH HHS / CA / CA62475; United States / NCI NIH HHS / CA / U01 CA069852; United States / NCI NIH HHS / CA / CA014599-289015
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / carmustine with prolifeprosan 20; 19916-73-5 / O(6)-benzylguanine; 5Z93L87A1R / Guanine; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; U68WG3173Y / Carmustine
  • [Other-IDs] NLM/ NIHMS66419; NLM/ PMC2556256
  •  go-up   go-down


44. Reman O, Pigneux A, Huguet F, Vey N, Delannoy A, Fegueux N, de Botton S, Stamatoullas A, Tournilhac O, Buzyn A, Charrin C, Boucheix C, Gabert J, Lhéritier V, Vernant JP, Fière D, Dombret H, Thomas X, GET-LALA group: Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: results from the GET-LALA group. Leuk Res; 2008 Nov;32(11):1741-50
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: results from the GET-LALA group.
  • Outcome of adult acute lymphoblastic leukemia (ALL) with central nervous system (CNS) involvement is not clearly defined.
  • We studied 104 patients presenting with CNS involvement at diagnosis among 1493 patients (7%) included into the LALA trials, and 109 patients presenting CNS disease at the time of first relapse among the 709 relapsing patients (15%).
  • Eighty-seven patients (84%) with CNS leukemia at diagnosis achieved complete remission (CR).
  • There were no significant differences in terms of CR, OS and DFS among patients with CNS involvement at diagnosis and those without CNS disease.
  • After a first relapse, 38 patients with CNS recurrence (35%) achieved a second CR.
  • Outcome was similar to that of relapsing patients without CNS disease.
  • CNS leukemia in adult ALL is uncommon at diagnosis as well as at the time of first relapse.
  • With intensification therapy, patients with CNS leukemia at diagnosis have a similar outcome than those who did not present with CNS involvement.
  • CNS leukemia at first relapse remains of similar poor prognosis than all other adult ALL in first relapse.
  • [MeSH-major] Central Nervous System Neoplasms / etiology. Neoplasm Recurrence, Local / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Incidence. Male. Middle Aged. Prognosis. Remission Induction. Stem Cell Transplantation. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18508120.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


45. Armstrong GT, Liu Q, Yasui Y, Huang S, Ness KK, Leisenring W, Hudson MM, Donaldson SS, King AA, Stovall M, Krull KR, Robison LL, Packer RJ: Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst; 2009 Jul 1;101(13):946-58
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study.
  • BACKGROUND: Adult survivors of childhood central nervous system (CNS) malignancies are at high risk for long-term morbidity and late mortality.
  • However, patterns of late mortality, the long-term risks of subsequent neoplasms and debilitating medical conditions, and sociodemographic outcomes have not been comprehensively characterized for individual diagnostic and treatment groups.
  • METHODS: We collected information on treatment, mortality, chronic medical conditions, and neurocognitive functioning of adult 5-year survivors of CNS malignancies diagnosed between 1970 and 1986 within the Childhood Cancer Survivor Study.
  • Using competing risk framework, we calculated cumulative mortality according to cause of death and cumulative incidence of subsequent neoplasms according to exposure and dose of cranial radiation therapy (RT).
  • Neurocognitive impairment and socioeconomic outcomes were assessed with respect to dose of CNS radiotherapy to specific brain regions.
  • Patients who received cranial RT of 50 Gy or more (n = 813) had a cumulative incidence of a subsequent neoplasm within the CNS of 7.1% (95% CI = 4.5% to 9.6%) at 25 years from diagnosis compared with 1.0% (95% CI = 0% to 2.3%) for patients who had no RT.
  • Neurocognitive impairment was high and proportional to radiation dose for specific tumor types.
  • CONCLUSIONS: Survivors of childhood CNS malignancies are at high risk for late mortality and for developing subsequent neoplasms and chronic medical conditions.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMJ. 1994 Jul 16;309(6948):162-6 [8044095.001]
  • [Cites] J Natl Cancer Inst. 2008 Oct 1;100(19):1368-79 [18812549.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3163-72 [11432882.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] J Neurol. 2002 Aug;249(8):955-60 [12195437.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):663-73 [12548609.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1115-26 [12569614.001]
  • [Cites] J Neurooncol. 2003 Jul;63(3):279-87 [12892234.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3255-61 [12947060.001]
  • [Cites] JAMA. 2003 Sep 24;290(12):1583-92 [14506117.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4731-9 [14557448.001]
  • [Cites] Pediatr Hematol Oncol. 2003 Dec;20(8):617-25 [14578032.001]
  • [Cites] Neuropsychology. 2003 Oct;17(4):548-55 [14599268.001]
  • [Cites] Curr Opin Neurol. 2003 Dec;16(6):677-83 [14624076.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):999-1006 [15020603.001]
  • [Cites] Ann Fam Med. 2004 Jan-Feb;2(1):61-70 [15053285.001]
  • [Cites] Cancer. 2004 May 15;100(10):2246-52 [15139071.001]
  • [Cites] J Clin Epidemiol. 2004 Sep;57(9):933-44 [15504636.001]
  • [Cites] Am J Epidemiol. 1986 Jan;123(1):174-84 [3509965.001]
  • [Cites] Am J Clin Oncol. 1985 Dec;8(6):472-6 [3936349.001]
  • [Cites] Arch Dis Child. 1990 Dec;65(12):1356-63 [2270944.001]
  • [Cites] J Clin Oncol. 1991 Apr;9(4):592-9 [2066756.001]
  • [Cites] J Clin Oncol. 1992 Sep;10(9):1397-406 [1517782.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2188-97 [18792068.001]
  • [Cites] Int J Epidemiol. 1998 Feb;27(1):91-5 [9563700.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1723-8 [9586884.001]
  • [Cites] Ann Neurol. 1998 Sep;44(3):313-6 [9749596.001]
  • [Cites] Med Pediatr Oncol. 1998 Dec;31(6):506-11 [9835903.001]
  • [Cites] Stat Med. 1999 Mar 30;18(6):695-706 [10204198.001]
  • [Cites] J Neurooncol. 1999 Jan;41(1):47-53 [10222422.001]
  • [Cites] Br J Cancer. 2004 Nov 29;91(11):1905-10 [15534607.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4979-90 [15576413.001]
  • [Cites] Pediatr Blood Cancer. 2005 Aug;45(2):155-61 [15880357.001]
  • [Cites] Pediatr Blood Cancer. 2006 May 1;46(5):637-44 [16421901.001]
  • [Cites] Pediatr Blood Cancer. 2006 Jul;47(1):83-8 [16317732.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2536-43 [16735706.001]
  • [Cites] Radiat Res. 2006 Jul;166(1 Pt 2):141-57 [16808603.001]
  • [Cites] Haematologica. 2006 Aug;91(8):1084-91 [16870549.001]
  • [Cites] N Engl J Med. 2006 Oct 12;355(15):1572-82 [17035650.001]
  • [Cites] Eur J Cancer. 2007 Jan;43(2):351-62 [17141498.001]
  • [Cites] Pediatr Blood Cancer. 2007 Apr;48(4):460-7 [16767717.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1532-8 [17442996.001]
  • [Cites] Pediatr Blood Cancer. 2007 Jul;49(1):47-51 [16755550.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4014-21 [18258798.001]
  • [Cites] Cancer. 2008 May 1;112(9):2071-9 [18327823.001]
  • [Cites] Pediatr Blood Cancer. 2008 Aug;51(2):245-50 [18386785.001]
  • [Cites] J Clin Oncol. 2008 Sep 20;26(27):4401-9 [18802152.001]
  • [CommentIn] J Natl Cancer Inst. 2009 Jul 1;101(13):908-10 [19549957.001]
  • [CommentIn] J Natl Cancer Inst. 2009 Jul 1;101(13):909 [19549959.001]
  • (PMID = 19535780.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24-CA55727
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2704230
  •  go-up   go-down


46. Sancho JM, Ribera JM, Oriol A, Hernandez-Rivas JM, Rivas C, Bethencourt C, Parody R, Deben G, Bello JL, Feliu E, Programa para el Estudio y Tratamiento de Hemopatias Malignas Group: Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis. Cancer; 2006 Jun 15;106(12):2540-6
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis.
  • Recurrence of acute lymphoblastic leukemia (ALL) in the central nervous system (CNS) confers a poor prognosis, although to the authors' knowledge, only a few studies have analyzed this issue in adults.
  • For the current study, the authors analyzed the frequency, predictive factors, and prognosis of CNS involvement and recurrence in adult patients with ALL who did not receive cranial irradiation for CNS prophylaxis.
  • Four hundred sixty-seven adult patients (age > or = 15 years) with ALL were treated on 4 protocols: ALL-89 (standard-risk and high-risk ALL; n = 108 patients), ALL-93 (high-risk ALL; n = 222 patients), ALL-96 (standard-risk ALL; n = 84 patients), and ALL3-97 (Burkitt leukemia; n = 53 patients).
  • CNS prophylaxis consisted of intrathecal methotrexate, cytarabine, and hydrocortisone together with high-dose systemic methotrexate and cytarabine.
  • CNS involvement at diagnosis was observed in 18 patients (3.9%).
  • Of 159 recurrences, 22 occurred (5.8%) in the CNS (14 isolated and 8 combined).
  • A lactate dehydrogenase level > 1000 U/L was the only factor associated with the risk of CNS recurrence.
  • The median overall survival after recurrence was 0.7 years for patients with isolated CNS recurrence, 0.13 years for patients with combined recurrence, and 0.41 years for patients with bone marrow recurrence (P = .11).
  • The frequency of CNS recurrence in adult patients with ALL who do not receive radiotherapy for CNS prophylaxis was similar to the frequency observed in protocols that included cranial irradiation.
  • A lactate dehydrogenase value >1000 U/L was the only factor found to be associated with CNS recurrence.
  • The prognosis for patients who develop CNS recurrence is poor, identical to that for patients who develop bone marrow recurrence.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Combined Modality Therapy. Cranial Irradiation. Cytarabine / administration & dosage. Female. Humans. Hydrocortisone / administration & dosage. Incidence. Lactate Dehydrogenases / analysis. Male. Methotrexate / administration & dosage. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Prognosis. Retrospective Studies. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16700036.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; EC 1.1.- / Lactate Dehydrogenases; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


47. Crawford JR, Santi MR, Cornelison R, Sallinen SL, Haapasalo H, MacDonald TJ: Detection of human herpesvirus-6 in adult central nervous system tumors: predominance of early and late viral antigens in glial tumors. J Neurooncol; 2009 Oct;95(1):49-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of human herpesvirus-6 in adult central nervous system tumors: predominance of early and late viral antigens in glial tumors.
  • The purpose is to determine the incidence of active and latent human herpesvirus-6 (HHV-6) infection in a large cohort of adult primary and recurrent CNS tumors.
  • We screened a tissue microarray (TMA) containing more than 200 adult primary and recurrent CNS tumors with known clinical information for the presence of HHV-6 DNA by in situ hybridization (ISH) and protein by immunohistochemistry (IHC).
  • One hundred six of 224 (47%) CNS tumors were positive for HHV-6 U57 Major Capsid Protein (MCP) gene by ISH compared to 0/25 non tumor control brain (P = 0.001).
  • Fourteen of 30 (47%) tumors were HHV-6 MCP positive by nested PCR compared to 0/25 non-tumor brain controls (P = 0.001), revealing HHV-6 Variant A in 6 of 14 samples.
  • HHV-6A/B early (p41) and late (gp116/64/54) antigens were detected by IHC in 66 of 277 (24%) (P = 0.003) and 84 of 282 (35%) (P = 0.002) tumors, respectively, suggesting active infection.
  • Glial tumors were 3 times more positive by IHC compared to non glial tumors for both HHV-6 gp116/64/54 (P = 0.0002) and HHV-6 p41 (P = 0.004).
  • HHV-6 early and late antigens are detected in adult primary and recurrent CNS tumors more frequently in glial tumors.
  • We hypothesize that the glial-tropic features of HHV-6 may play an important modifying role in tumor biology that warrants further investigation.
  • [MeSH-major] Antigens, Viral. Central Nervous System Neoplasms / genetics. Central Nervous System Neoplasms / virology. Glioma / genetics. Glioma / virology. Herpesvirus 6, Human / isolation & purification
  • [MeSH-minor] Adult. Antigens, CD / metabolism. CD48 Antigen. Capsid Proteins / genetics. Capsid Proteins / metabolism. Humans. Survival Analysis. Viral Envelope Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19424665.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / K12NS052159-01A
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Viral; 0 / CD48 Antigen; 0 / Capsid Proteins; 0 / Viral Envelope Proteins
  •  go-up   go-down


48. Adams DM, Zhou T, Berg SL, Bernstein M, Neville K, Blaney SM, Children's Oncology Group: Phase 1 trial of O6-benzylguanine and BCNU in children with CNS tumors: a Children's Oncology Group study. Pediatr Blood Cancer; 2008 Mar;50(3):549-53
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 1 trial of O6-benzylguanine and BCNU in children with CNS tumors: a Children's Oncology Group study.
  • O(6)-benzylguanine (O(6)-BG), an inhibitor of host alkylation repair, and BCNU were studied in children with refractory/untreatable central nervous system tumors to determine dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of BCNU administered following O(6)-BG.
  • Once the MTD was exceeded, Stage II accrual was limited to less heavily pretreated patients (</= two prior chemotherapy regimens, no prior central axis radiation, no prior bone marrow transplant, and no bone marrow involvement).
  • CONCLUSIONS: Based on lack of activity of this combination in adult phase II studies, no further testing of O(6)-BG plus BCNU in children is planned.
  • [MeSH-major] Antineoplastic Agents, Alkylating / pharmacology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carmustine / pharmacology. Central Nervous System Neoplasms / drug therapy. Guanine / analogs & derivatives. Neoplasm Proteins / antagonists & inhibitors. O(6)-Methylguanine-DNA Methyltransferase / antagonists & inhibitors
  • [MeSH-minor] Adolescent. Bone Marrow Diseases / chemically induced. Child. Child, Preschool. Cohort Studies. Combined Modality Therapy. DNA Repair / drug effects. DNA, Neoplasm / drug effects. Enzyme Inhibitors / administration & dosage. Enzyme Inhibitors / pharmacology. Enzyme Inhibitors / therapeutic use. Female. Humans. Male. Maximum Tolerated Dose. Salvage Therapy

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17941066.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 97543; United States / NCRR NIH HHS / RR / M01 RR00188; United States / NCI NIH HHS / CA / U01 CA97552
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / DNA, Neoplasm; 0 / Enzyme Inhibitors; 0 / Neoplasm Proteins; 19916-73-5 / O(6)-benzylguanine; 5Z93L87A1R / Guanine; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; U68WG3173Y / Carmustine
  •  go-up   go-down


49. Idowu MO, Rosenblum MK, Wei XJ, Edgar MA, Soslow RA: Ependymomas of the central nervous system and adult extra-axial ependymomas are morphologically and immunohistochemically distinct--a comparative study with assessment of ovarian carcinomas for expression of glial fibrillary acidic protein. Am J Surg Pathol; 2008 May;32(5):710-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ependymomas of the central nervous system and adult extra-axial ependymomas are morphologically and immunohistochemically distinct--a comparative study with assessment of ovarian carcinomas for expression of glial fibrillary acidic protein.
  • We reviewed the morphologic and immunohistochemical features of 5 extra-axial ependymomas occurring in adults, 1 arising in an infantile sacrococcygeal teratoma, and a control group of 10 central nervous system (CNS) ependymomas in adults.
  • The adult extra-axial cases demonstrated more architectural variability than the CNS cases.
  • We observed that both the CNS and adult extra-axial ependymomas expressed GFAP diffusely, whereas only 9 stage III, high-grade ovarian serous papillary carcinomas stained with GFAP (2 strongly and diffusely and 7 exhibiting focally weak expression).
  • There were significant immunophenotypic differences between adult extra-axial and CNS ependymomas, with extra-axial cases preferentially expressing 34betaE12 (60% vs. 0%), CK18 (100% vs. 20%), CAM 5.2 (60% vs. 10%), CK7 (80% vs. 10%), ER (100% vs. 10%), and PR (80% vs. 20%).
  • CNS ependymomas more frequently expressed CD99 (100% vs. 20%).
  • The following stains were not differentially expressed: epithelial membrane antigen (expressed in 2 of 15 cases, including both extra-axial and CNS ependymomas), synaptophysin (1/15), chromogranin (0/15), WT1 (8/15), AE1:3 (10/15), and CK20 (0/15).
  • The ependymal elements of the sacrococcygeal tumor failed to express 34betaE12, CK18, CAM 5.2, and CK7, like most CNS ependymomas.
  • The morphologic and immunophenotypic differences between extra-axial and CNS ependymomas suggest that they derive from distinct precursors and/or differentiate along distinct pathways.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Central Nervous System Neoplasms / metabolism. Ependymoma / metabolism. Glial Fibrillary Acidic Protein / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Immunoenzyme Techniques. Infant. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18360284.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


50. Lancashire ER, Frobisher C, Reulen RC, Winter DL, Glaser A, Hawkins MM: Educational attainment among adult survivors of childhood cancer in Great Britain: a population-based cohort study. J Natl Cancer Inst; 2010 Feb 24;102(4):254-70
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Educational attainment among adult survivors of childhood cancer in Great Britain: a population-based cohort study.
  • Statistically significant deficits were restricted to central nervous system (CNS) neoplasm and leukemia survivors.
  • Odds ratios for achievement by irradiated CNS tumor survivors were 50%-74% of those for cranially irradiated leukemia or nonirradiated CNS tumor survivors.
  • Survivors at greater risk of poorer educational outcomes included those treated with cranial irradiation, diagnosed with a CNS tumor, older at questionnaire completion, younger at diagnosis, diagnosed with epilepsy, and who were female.
  • [MeSH-major] Cranial Irradiation / adverse effects. Educational Status. Neoplasms. Survivors / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Age Factors. Brain Neoplasms / radiotherapy. Child. Child, Preschool. Cohort Studies. Female. Great Britain / epidemiology. Humans. Male. Quality of Life. Surveys and Questionnaires. Time Factors. Young Adult

  • Genetic Alliance. consumer health - Childhood Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20107164.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / C386/A10422; United Kingdom / Cancer Research UK / / C386/A3727; United Kingdom / Cancer Research UK / / C386/A7852
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


51. Mekni A, Kourda J, Chelly I, Ferchichi L, Bellil K, Hammouda KB, Kchir N, Zitouna M, Khaldi M, Haouet S: Hemangiopericytoma in the central nervous system. A study of eight cases. Neurochirurgie; 2008 Feb;54(1):15-20
Genetic Alliance. consumer health - Hemangiopericytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemangiopericytoma in the central nervous system. A study of eight cases.
  • Most hemangiopericytomas (HPC) are located in the musculoskeletal system and the skin, while the location in the central nervous system (CNS) is rare.
  • The latter represents 2 to 4% in large series of meningeal tumors, thus accounting for less than 1% of all CNS tumors.
  • In the central nervous system, tumors with a hemangiopericytomatous histolopathological pattern can be either hemangiopericytomas or solitary fibrous tumors.
  • CNS-HPCs have a relentless tendency for local recurrence and metastases outside the CNS.
  • Metastasis can also appear many years after adequate treatment of the primary tumor.
  • We present a pathological study of eight patients with CNS-HPC and compare our results with corresponding published data.
  • The CNS-HPC group consisted of three males and five females with a mean age of 36.75 years.
  • The tumors were supratentorial in four cases, infratentorial in two cases, tentorial in one case and located in the spinal cord in the last one.
  • Histologically, CNS-HPCs were similar to their soft tissue counterparts.
  • Our study presents the pathological features of CNS-HPC as a distinct entity from both meningioma and solitary fibrous tumors.
  • [MeSH-major] Central Nervous System Neoplasms / surgery. Hemangiopericytoma / surgery
  • [MeSH-minor] Adult. Antigens, CD34 / metabolism. Female. Humans. Immunohistochemistry. Infratentorial Neoplasms / pathology. Infratentorial Neoplasms / surgery. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neuroglia / pathology. Neurosurgical Procedures. Spinal Cord Neoplasms / pathology. Spinal Cord Neoplasms / surgery. Supratentorial Neoplasms / pathology. Supratentorial Neoplasms / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18308345.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


52. Arshad H, Ahmad Z, Hasan SH: Gliomas: correlation of histologic grade, Ki67 and p53 expression with patient survival. Asian Pac J Cancer Prev; 2010;11(6):1637-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Grade is the most significant prognostic factor determining survival, but various proliferation markers are being increasingly employed by histopathologists as adjuncts to conventional morphologic variables to determine prognostic behavior of brain tumors.
  • OBJECTIVE: To correlate World Health Organization (WHO) grades of glial neoplasms and expression of MIB1 and P53 by these tumors with patient survival at the end of one year.
  • MATERIAL AND METHODS: 50 consecutive cases with confirmed diagnosis of various histologic types of glial neoplasms were included.
  • Grading was done according to the WHO grading system for CNS neoplasms.
  • CONCLUSION: Histologic grade is the most important prognostic factor with respect to patient survival in glial neoplasms.
  • Immunohistochemical staining with MIB1 and p53 may serve as an additional useful toolin determining the clinical course in combination with and as an adjunct to tumor grade.
  • [MeSH-major] Brain Neoplasms / metabolism. Brain Neoplasms / mortality. Glioma / metabolism. Glioma / mortality. Ki-67 Antigen / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21338209.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


53. Kim SJ, Oh SY, Hong JY, Chang MH, Lee DH, Huh J, Ko YH, Ahn YC, Kim HJ, Suh C, Kim K, Kim WS: When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type? Ann Oncol; 2010 May;21(5):1058-63
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type?
  • BACKGROUND: The incidence and risk factors of central nervous system (CNS) invasion is still unclear in extranodal natural killer (NK)/T-cell lymphoma, nasal type.
  • PATIENTS AND METHODS: We analyzed 208 patients to study the clinical features and outcomes of CNS disease in extranodal NK/T-cell lymphoma.
  • RESULTS: Twelve patients (5.76%, 12/208) experienced CNS disease during treatment or follow-up period (median 11.62 months, range 0.2-123.2 months).
  • The clinical variables associated with CNS disease were Ann Arbor stage III/IV (15.87%, P <0.001), regional lymph node involvement (10.41%, P = 0.006), group III/IV of NK/T-cell lymphoma prognostic index (NKPI; 10.20%, P = 0.003), high/high-intermediate international prognostic index (9.30%, P = 0.072) and extra-upper aerodigestive primary sites (9.75%, P = 0.008).
  • In multivariate analysis, NKPI retained the strongest statistical power to predict CNS disease (P = 0.007, relative risk 9.289, 95% confidence interval 1.828-47.212) in extranodal NK/T-cell lymphoma.
  • CONCLUSIONS: Despite extranodal NK/T-cell lymphoma frequently involves paranasal sinus, a routine CNS evaluation and prophylaxis do not seem to be necessary in NKPI group I or II patients due to a very low incidence.
  • Nevertheless, CNS prophylaxis should be considered in NKPI groups III and IV.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19850636.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


54. Nicoletti F, Arcella A, Iacovelli L, Battaglia G, Giangaspero F, Melchiorri D: Metabotropic glutamate receptors: new targets for the control of tumor growth? Trends Pharmacol Sci; 2007 May;28(5):206-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabotropic glutamate receptors: new targets for the control of tumor growth?
  • Cancer stem cells are currently a target for the treatment of malignant tumors.
  • Transformed neural stem-progenitor cells of the brain subventricular zone and the external granular layer of the cerebellum are the putative cells of origin of malignant gliomas and medulloblastomas, which are the most frequent malignant brain tumors in adults and children, respectively.
  • The proliferation of neural stem-progenitor cells is regulated by metabotropic glutamate (mGlu) receptors, which are G-protein-coupled receptors that are activated by glutamate, the major excitatory neurotransmitter of the CNS.
  • At least two receptor subtypes - mGlu(3) and mGlu(4) receptors - control the proliferation of brain tumor cells, whereas mGlu(1) receptors have been implicated in the development of melanomas.
  • We believe that individual mGlu receptor subtypes represent new potential targets for the treatment of several malignant tumors, including brain tumors.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Brain Neoplasms / drug therapy. Drug Delivery Systems. Receptors, Metabotropic Glutamate / drug effects
  • [MeSH-minor] Adult. Animals. Cell Proliferation. Child. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / physiopathology. Drug Resistance, Neoplasm. Gene Expression. Humans. Ligands. Melanoma / drug therapy. Melanoma / physiopathology. Neoplastic Stem Cells / drug effects. Skin Neoplasms / drug therapy. Skin Neoplasms / physiopathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17433452.001).
  • [ISSN] 0165-6147
  • [Journal-full-title] Trends in pharmacological sciences
  • [ISO-abbreviation] Trends Pharmacol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ligands; 0 / Receptors, Metabotropic Glutamate
  •  go-up   go-down


55. Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, Schmitz N, German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL): Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol; 2007 Jan;18(1):149-57
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
  • BACKGROUND: Central nervous system (CNS) relapse is a devastating and usually fatal complication of aggressive lymphoma.
  • We analyzed the patients treated on protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) between 1990 and 2000, evaluated the rate and prognostic factors for CNS recurrence and developed a risk model trying to identify subsets of patients suitable for future prophylactic strategies.
  • RESULTS: A total number of 1711 patients were initially eligible for this study, of whom 18 patients had to be excluded due to primary CNS involvement.
  • In the remaining 1693 assessable patients, 37 cases of relapse or progression to the CNS (2.2%) were observed.
  • Multivariate Cox regression analysis identified increased LDH (P<0.001) and involvement of more than one extranodal site (P=0.002) as independent predictors of CNS recurrence in the NHL-B1/B2 study population.
  • Treatment with etoposide also evolved as a prognostic factor because the risk of CNS failure was significantly reduced after CHOEP (P=0.017).
  • Elderly patients presenting with both an elevated LDH and lymphoma involvement in liver, bladder or adrenals had an up to 15-fold risk of spread of the disease to the CNS.
  • CONCLUSION: The incidence of CNS relapse in 1693 patients treated for aggressive lymphomas on DSHNHL protocols from 1990 to 2000 was low (2.2%), although CNS prophylaxis was administered to <5% of patients.
  • A cumulative 20% incidence of CNS disease in certain prognostic subgroups of elderly patients may render these candidates for i.th. prophylaxis; however, this approach would imply a potential overtreatment of approximately 80% of these patients deemed at high risk.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17018708.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VB0R961HZT / Prednisone
  •  go-up   go-down


56. von Boxberg Y, Salim C, Soares S, Baloui H, Alterio J, Ravaille-Veron M, Nothias F: Spinal cord injury-induced up-regulation of AHNAK, expressed in cells delineating cystic cavities, and associated with neoangiogenesis. Eur J Neurosci; 2006 Aug;24(4):1031-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate the molecular basis for the poor regenerative capacity of the mammalian central nervous system (CNS) after injury, we searched for genes whose expression was affected by an adult rat spinal cord hemi-section.
  • A striking overexpression was found for ahnak, encoding a 700-kDa protein, in normal CNS present only in the blood-brain barrier (BBB) forming vascular endothelial cells.
  • [MeSH-major] Membrane Proteins / metabolism. Neoplasm Proteins / metabolism. Neovascularization, Physiologic. Nerve Regeneration. Spinal Cord Injuries

  • MedlinePlus Health Information. consumer health - Spinal Cord Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16930430.001).
  • [ISSN] 0953-816X
  • [Journal-full-title] The European journal of neuroscience
  • [ISO-abbreviation] Eur. J. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Ahnak protein, rat; 0 / Membrane Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


57. Freeman BB 3rd, Daw NC, Geyer JR, Furman WL, Stewart CF: Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients. Cancer Invest; 2006 Apr-May;24(3):310-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients.
  • EGFR expression has been noted in neuroblastoma and rhabdomyosarcoma cell lines and in tumor specimens from children with Wilms tumor, osteosarcoma, and glioma.
  • Thus, gefitinib, the first marketed EGFR tyrosine kinase inhibitor, was chosen for study in children with refractory solid tumors and central nervous system (CNS) malignancies.
  • This review discusses findings from 3 clinical trials of gefitinib in children with refractory solid tumors and CNS malignancies, focusing on the clinical pharmacology of the compound.
  • Finally, the future for the use of gefitinib in pediatrics is similar to that of other molecularly targeted agents and awaits definition of tumors and patient populations in which it will be most advantageous.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Central Nervous System Neoplasms / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Child. Clinical Trials as Topic. Drug Resistance, Neoplasm. Humans. Receptor, Epidermal Growth Factor / drug effects. Receptor, Epidermal Growth Factor / metabolism

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16809160.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; 7673326042 / irinotecan; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 67
  •  go-up   go-down


58. Hoei-Hansen CE, Sehested A, Juhler M, Lau YF, Skakkebaek NE, Laursen H, Rajpert-de Meyts E: New evidence for the origin of intracranial germ cell tumours from primordial germ cells: expression of pluripotency and cell differentiation markers. J Pathol; 2006 May;209(1):25-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary intracranial germ cell tumours are rare neoplasms that occur in children and adolescents.
  • TSPY was only detected in germ cell tumours in the central nervous system (CNS) from males, suggesting that it is not required for the initiation of malignant germ cell transformation.
  • The expression of genes associated with embryonic stem cell pluripotency in CNS germ cell tumours strongly suggests that these tumours are derived from cells that retain, at least partially, an embryonic stem cell-like phenotype, which is a hallmark of primordial germ cells.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasms, Germ Cell and Embryonal / pathology. Neoplastic Stem Cells / pathology. Pluripotent Stem Cells / pathology
  • [MeSH-minor] Adolescent. Adult. Antigens, Differentiation / metabolism. Cell Differentiation. Child. Child, Preschool. Embryonal Carcinoma Stem Cells. Female. Gene Expression. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Infant. Infant, Newborn. Male. Neoplasm Proteins / metabolism. Stromal Cells / metabolism. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 16456896.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Differentiation; 0 / Neoplasm Proteins; 0 / Transcription Factors
  •  go-up   go-down


59. Zhang Y, Martens JW, Yu JX, Jiang J, Sieuwerts AM, Smid M, Klijn JG, Wang Y, Foekens JA: Copy number alterations that predict metastatic capability of human breast cancer. Cancer Res; 2009 May 1;69(9):3795-801
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have analyzed the DNA copy numbers for over 100,000 single-nucleotide polymorphism loci across the human genome in genomic DNA from 313 lymph node-negative primary breast tumors for which genome-wide gene expression data were also available.
  • In the training set of 200 patients, we constructed an 81-gene prognostic copy number signature (CNS) that identified a subgroup of patients with increased probability of distant metastasis in the independent validation set of 113 patients [hazard ratio (HR), 2.8; 95% confidence interval (95% CI), 1.4-5.6] and in an external data set of 116 patients (HR, 3.7; 95% CI, 1.3-10.6).
  • This very poor prognostic group identified by CNS and GES was putatively more resistant to preoperative paclitaxel and 5-fluorouracil-doxorubicin-cyclophosphamide combination chemotherapy (P = 0.0048), particularly against the doxorubicin compound, while potentially benefiting from etoposide.
  • When combined with gene expression-based signatures for prognosis, the CNS refines risk classification and can help identify those breast cancer patients who have a significantly worse outlook in prognosis and a potential differential response to chemotherapeutic drugs.
  • [MeSH-major] Breast Neoplasms / genetics. Chromosome Aberrations. Gene Dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA, Neoplasm / genetics. Female. Gene Expression Profiling. Genetic Predisposition to Disease. Humans. Middle Aged. Neoplasm Metastasis. Polymorphism, Single Nucleotide. Receptors, Estrogen / biosynthesis

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19336569.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Receptors, Estrogen
  •  go-up   go-down


60. Khattab AZ, Ahmed MI, Fouad MA, Essa WA: Significance of p53 and CD31 in astrogliomas. Med Oncol; 2009;26(1):86-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Astrogliomas are the most common primary brain tumor.
  • Its progression is the result of activation of oncogenes, inactivation of tumor suppressor genes (TSGs), and expression of various growth factors.
  • Sections were stained with hematoxylin and eosin to determine the type and histological grade according to WHO (2007) classification of CNS tumors.
  • Immunostaining was done using anti p53 and CD31 and the results were measured as labeling index (LI) using image analyzer system CAS-200.
  • Obviously, these observations demonstrate that the co-expression and increased levels of p53 and CD31 in astrogliomas are increasing as the tumor grade is increasing.
  • CONCLUSION: The estimation of p53 and CD31 could be used as good tools to assess the grade, prognosis, and aggressiveness of the astroglial tumors.
  • [MeSH-major] Antigens, CD31 / biosynthesis. Astrocytoma / metabolism. Biomarkers, Tumor. Brain Neoplasms / metabolism. Tumor Suppressor Protein p53 / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Immunohistochemistry. Infant. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18821037.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


61. Kivisäkk P, Tucky B, Wei T, Campbell JJ, Ransohoff RM: Human cerebrospinal fluid contains CD4+ memory T cells expressing gut- or skin-specific trafficking determinants: relevance for immunotherapy. BMC Immunol; 2006 Jul 07;7:14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We reasoned that a bias (either enrichment or depletion) of CSF T cell expression of known organ-specific trafficking determinants might suggest that homing of T cells to the subarachnoid space could be governed by a CNS-specific adhesion molecule or chemokine receptor.
  • Furthermore, the ready access of skin- and gut-homing CD4+ memory T cells to the CNS compartment via CSF has implications for the mechanisms of action of immunotherapeutic strategies, such as oral tolerance or therapeutic immunization, where immunogens are administered using an oral or subcutaneous route.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1998 Jun 15;91(12):4444-50 [9616137.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8389-94 [12829791.001]
  • [Cites] J Immunol. 1998 Dec 1;161(11):6413-20 [9834133.001]
  • [Cites] Adv Immunol. 1999;72:209-53 [10361577.001]
  • [Cites] Nature. 1999 Aug 19;400(6746):776-80 [10466728.001]
  • [Cites] Immunity. 2005 Feb;22(2):175-84 [15723806.001]
  • [Cites] J Immunol. 2005 May 1;174(9):5805-13 [15843584.001]
  • [Cites] Trends Immunol. 2005 Sep;26(9):485-95 [16039904.001]
  • [Cites] Ann Neurol. 2006 May;59(5):743-7 [16634029.001]
  • [Cites] J Exp Med. 1999 Nov 1;190(9):1241-56 [10544196.001]
  • [Cites] J Immunol. 1999 Dec 1;163(11):6236-43 [10570316.001]
  • [Cites] J Exp Med. 2000 Sep 4;192(5):761-8 [10974041.001]
  • [Cites] J Immunol. 2001 Feb 15;166(4):2842-8 [11160352.001]
  • [Cites] Neuroreport. 2001 Mar 5;12(3):601-6 [11234772.001]
  • [Cites] Ernst Schering Res Found Workshop. 2004;(47):133-54 [15032058.001]
  • [Cites] Trends Immunol. 2004 Mar;25(3):132-7 [15036040.001]
  • [Cites] J Immunol. 1993 Feb 1;150(3):1122-36 [7678617.001]
  • [Cites] Ann Neurol. 1993 Aug;34(2):155-61 [8338339.001]
  • [Cites] J Immunol. 1996 May 15;156(10):3727-36 [8621908.001]
  • [Cites] Clin Immunol Immunopathol. 1996 Sep;80(3 Pt 2):S31-9 [8811061.001]
  • [Cites] J Exp Med. 1998 Jan 5;187(1):129-34 [9419219.001]
  • [Cites] J Clin Invest. 1998 Feb 15;101(4):746-54 [9466968.001]
  • [Cites] J Exp Med. 1998 Mar 16;187(6):875-83 [9500790.001]
  • [Cites] Ann Neurol. 2001 Jul;50(1):121-7 [11456302.001]
  • [Cites] J Pathol. 2001 Aug;194(4):398-405 [11523046.001]
  • [Cites] J Clin Invest. 2001 Nov;108(9):1331-9 [11696578.001]
  • [Cites] J Mol Neurosci. 2001 Oct;17(2):259-67 [11816797.001]
  • [Cites] J Exp Med. 2002 Jan 7;195(1):135-41 [11781372.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):347-55 [11786428.001]
  • [Cites] Nat Med. 2002 Feb;8(2):157-65 [11821900.001]
  • [Cites] J Immunol. 2002 Feb 15;168(4):1940-9 [11823530.001]
  • [Cites] J Immunol. 2002 Jul 15;169(2):1000-6 [12097407.001]
  • [Cites] J Neuroimmunol. 2002 Aug;129(1-2):51-7 [12161020.001]
  • [Cites] Clin Exp Immunol. 2002 Sep;129(3):510-8 [12197893.001]
  • [Cites] J Hepatol. 2003 Jan;38(1):67-75 [12480562.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):879-84 [12490962.001]
  • [Cites] CNS Drugs. 2003;17(7):457-74 [12751917.001]
  • [Cites] Trends Neurosci. 2003 Jun;26(6):297-302 [12798598.001]
  • [Cites] J Immunol. 1998 Jul 15;161(2):963-70 [9670976.001]
  • (PMID = 16824229.001).
  • [ISSN] 1471-2172
  • [Journal-full-title] BMC immunology
  • [ISO-abbreviation] BMC Immunol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI046784; United States / NIAID NIH HHS / AI / R21 AI046784; United States / NINDS NIH HHS / NS / P01 NS038667; United States / NINDS NIH HHS / NS / P01 NS38667; United States / NINDS NIH HHS / NS / P50 NS038667
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Antigens, Neoplasm; 0 / CC chemokine receptor 9; 0 / CCR4 protein, human; 0 / CTAGE1 protein, human; 0 / Integrins; 0 / Membrane Glycoproteins; 0 / Receptors, CCR; 0 / Receptors, CCR4; 0 / Receptors, Chemokine; 0 / integrin alpha4beta7
  • [Other-IDs] NLM/ PMC1539023
  •  go-up   go-down


62. Jalali R, Srinivas C, Nadkarni TD, Rajasekharan P: Suprasellar haemangiopericytoma--challenges in diagnosis and treatment. Acta Neurochir (Wien); 2008 Jan;150(1):67-71

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Haemangiopericytomas of central nervous system (CNS) were first defined as a separate entity in 1942.
  • Previously they were either considered to be a histological variant of an angioblastic meningioma or a distinctive mesenchymal neoplasm.
  • [MeSH-major] Central Nervous System Cysts / diagnosis. Central Nervous System Cysts / therapy. Hemangiopericytoma / diagnosis. Hemangiopericytoma / therapy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / therapy. Sella Turcica
  • [MeSH-minor] Adult. Craniotomy. Diagnosis, Differential. Humans. Male. Middle Aged. Neoplasm, Residual. Pituitary Neoplasms / diagnosis. Radiotherapy, Adjuvant. Reoperation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18176777.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 18
  •  go-up   go-down


63. Yamamoto T, Tsuji S: [Anti-Ma2-associated encephalitis and paraneoplastic limbic encephalitis]. Brain Nerve; 2010 Aug;62(8):838-51
Genetic Alliance. consumer health - Limbic encephalitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The corresponding antigen, Ma2 is selectively expressed intracellularly in neurons and tumors as is the case with other onconeuronal antigens targeted by classical antibodies.
  • Some patients develop mesodiencephalic encephalitis with minor involvement of the limbic system, and some may manifest severe hypokinesis.
  • While it can cause severe neurological deficits or death in a substantial proportion of the patients, approximately one-third show neurological improvement and another 20 - 40% stabilize in response to treatment, including immunotherapy and/or tumor treatment.
  • Patients who have limited CNS involvement and testicular tumors with complete response to therapy are more likely to show neurological improvement.
  • In this respect, it is useful to highlight that anti-Ma2 encephalitis is almost always associated with testicular germ cell tumors in men younger than 50 years.
  • We experienced a 40-year-old patient with severe hypokinesis caused by anti-Ma2 encephalitis associated with bilateral intratubular germ-cell neoplasm of the testes.
  • [MeSH-major] Antigens, Neoplasm / immunology. Autoantibodies. Limbic Encephalitis. Nerve Tissue Proteins / immunology
  • [MeSH-minor] Adult. Animals. Biomarkers / blood. Biomarkers / cerebrospinal fluid. Carcinoma, Non-Small-Cell Lung. Diagnosis, Differential. Female. Humans. Lung Neoplasms. Male. Middle Aged. Neoplasms, Germ Cell and Embryonal. Prognosis. Testicular Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20714032.001).
  • [ISSN] 1881-6096
  • [Journal-full-title] Brain and nerve = Shinkei kenkyū no shinpo
  • [ISO-abbreviation] Brain Nerve
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Autoantibodies; 0 / Biomarkers; 0 / Ma2 antigen; 0 / Nerve Tissue Proteins
  •  go-up   go-down


64. Klabusay M, Pevná M, Kissová J, Doubek M, Heidekerová M, Mayer J, Vorlícek J: [Rare diagnosis of CD4+56+ leukemia from dendritic cells type DC2]. Cas Lek Cesk; 2008;147(10):511-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CD4+56+ hematodermic neoplasm or leukemia from early plasmocytoid dendritic cells type DC2 was recognized by WHO-EORTC classification of cutaneous lymphomas as a separate entity related to the plasmacytoid precursor dendritic cell (pDC).
  • However, this aggressive disease requires radical approach with intensive chemotherapy regimens, prophylaxis of CNS involvement and early indication of allogeneic bone marrow transplantation.
  • [MeSH-major] Antigens, CD4 / analysis. Antigens, CD56 / analysis. Dendritic Cells / immunology. Leukemia / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19177732.001).
  • [ISSN] 0008-7335
  • [Journal-full-title] Casopís lékar̆ů c̆eských
  • [ISO-abbreviation] Cas. Lek. Cesk.
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Antigens, CD56
  • [Number-of-references] 26
  •  go-up   go-down


65. Bafford AC, Burstein HJ, Barkley CR, Smith BL, Lipsitz S, Iglehart JD, Winer EP, Golshan M: Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. Breast Cancer Res Treat; 2009 May;115(1):7-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ER and Her2neu status were positive predictors of survival (HR: 0.191 and 0.285 P < 0.0001); CNS and liver metastases were adverse predictors (HR: 2.05 and 1.59 P = 0.015 P = 0.059).
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / surgery. Carcinoma / diagnosis. Carcinoma / surgery. Neoplasm Staging / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Mastectomy / methods. Mastectomy, Segmental / methods. Middle Aged. Predictive Value of Tests. Proportional Hazards Models. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18581232.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 13
  •  go-up   go-down


66. Mahfouz S, Aziz AA, Gabal SM, el-Sheikh S: Immunohistochemical study of CD99 and EMA expression in ependymomas. Medscape J Med; 2008;10(2):41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors of the central nervous system (CNS) represent a unique, heterogeneous population of neoplasms and include both benign and malignant tumors.
  • The present study was carried out on a total of 79 archival cases of ependymal tumors in addition to a variety of other primary CNS tumors.
  • Upon comparing with other CNS tumors (41 cases), it was found that CD99 could differentiate between ependymomas and nonependymal tumors, but intensity and pattern of staining were of no consequence in determining variant type or degree of histologic aggressiveness.
  • CD99 can hence be recommended for use as a good marker for differentiation between ependymal and other CNS tumors.
  • EMA expression and pattern of distribution, on the other hand, cannot be employed to determine the type of variant or the degree of tumor aggressiveness, and hence cannot predict the behavior of ependymal neoplasms.
  • [MeSH-major] Antigens, CD / analysis. Biomarkers, Tumor / analysis. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Cell Adhesion Molecules / analysis. Ependymoma / diagnosis. Ependymoma / metabolism. Mucin-1 / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Gene Expression Profiling. Humans. Infant. Infant, Newborn. Male. Middle Aged. Neoplasm Proteins / analysis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Mar;8(1):25-31 [10937045.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Jun;9(2):125-9 [11396629.001]
  • [Cites] Diagn Cytopathol. 2002 Apr;26(4):247-50 [11933271.001]
  • [Cites] J Neurooncol. 2002 May;58(1):13-9 [12160136.001]
  • [Cites] Exp Mol Med. 2002 Jul 31;34(3):177-83 [12216109.001]
  • [Cites] Acta Neuropathol. 2003 Oct;106(4):385-8 [12898159.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):980-91 [14559980.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1721-7 [14578171.001]
  • [Cites] Curr Treat Options Oncol. 2003 Dec;4(6):517-23 [14585232.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1230-7 [15022291.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Mar;63(3):185-92 [15055442.001]
  • [Cites] Neuropathol Appl Neurobiol. 1988 May-Jun;14(3):197-205 [3405393.001]
  • [Cites] Cancer Res. 1988 Nov 1;48(21):6127-31 [2844401.001]
  • [Cites] Acta Neuropathol. 1989;78(3):325-8 [2763805.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;417(2):97-103 [1695040.001]
  • [Cites] Arch Pathol Lab Med. 1990 Sep;114(9):956-60 [2390011.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):1886-93 [1848471.001]
  • [Cites] Acta Neuropathol. 1991;82(3):208-16 [1718129.001]
  • [Cites] Am J Surg Pathol. 1994 May;18(5):486-94 [7513503.001]
  • [Cites] J Neurooncol. 2005 Jan;71(2):189-93 [15690137.001]
  • [Cites] Brain Tumor Pathol. 2004;21(1):17-21 [15696964.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2598-605 [15861411.001]
  • [Cites] Histopathology. 2007 Feb;50(3):365-70 [17257132.001]
  • [Cites] J Neurooncol. 2002 Jul;58(3):255-70 [12187959.001]
  • [Cites] Acta Neuropathol. 1997 Mar;93(3):310-6 [9083565.001]
  • [Cites] Neuropathology. 2004 Dec;24(4):330-5 [15641594.001]
  • [Cites] Pathol Res Pract. 2004;200(10):717-25 [15648610.001]
  • (PMID = 18382710.001).
  • [ISSN] 1934-1997
  • [Journal-full-title] Medscape journal of medicine
  • [ISO-abbreviation] Medscape J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Mucin-1; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2270873
  •  go-up   go-down


67. Kitzmann AS, Pulido JS, Garrity JA, Witzig TE: Histologic findings in T-cell lymphoma infiltration of the optic nerve. Ophthalmology; 2008 May;115(5):e1-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A 39-year-old man with a diagnosis of peripheral T-cell NHL, stage IV, with CNS involvement and decreased vision was found to have lymphomatous infiltration of the optic nerves.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Lymphoma, T-Cell / pathology. Optic Nerve / pathology
  • [MeSH-minor] Adult. Antigens, CD20 / metabolism. Antigens, CD3 / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Neoplasm Staging. Radiotherapy, Adjuvant. Visual Acuity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18321583.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3
  •  go-up   go-down


68. Kosmas C, Tsavaris N, Mylonakis N, Tsakonas G, Gassiamis A, Skopelitis H, Polyzos A, Malamos N, Karabelis A: Docetaxel-ifosfamide combination in patients with advanced breast cancer failing prior anthracycline-based regimens: results of a phase I-II study. J Chemother; 2007 Jun;19(3):322-31
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Other toxicities included peripheral neuropathy grade 2 only in 10%, grade 1/2 reversible CNS toxicity in 16%, no renal toxicity, grade 2 myalgias in 8%, grade 3 diarrhea in 8%, skin/nail toxicity in 14%, and grade 2 fluid retention in 2% of patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Dose-Response Relationship, Drug. Female. Granulocyte Colony-Stimulating Factor. Humans. Ifosfamide / administration & dosage. Maximum Tolerated Dose. Middle Aged. Neoplasm Metastasis. Recombinant Proteins. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17594929.001).
  • [ISSN] 1120-009X
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Recombinant Proteins; 0 / Taxoids; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 15H5577CQD / docetaxel; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


69. De Sio L, Milano GM, Castellano A, Jenkner A, Fidani P, Dominici C, Donfrancesco A: Temozolomide in resistant or relapsed pediatric solid tumors. Pediatr Blood Cancer; 2006 Jul;47(1):30-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide in resistant or relapsed pediatric solid tumors.
  • PURPOSE: We report the off-label study aimed at investigating the use of temozolomide (TMZ) as single agent in relapsed or resistant pediatric solid tumors.
  • PATIENTS AND METHODS: Fifty two patients, median age 127.6 months, with resistant or relapsed solid tumors were enrolled.
  • Tumor types were: neuroblastoma (NB; n = 17), medulloblastoma (MB; 8), brain stem glioma (BSG; 8), extraosseous Ewing's sarcoma/peripheral neuroectodermal tumor (EOES; 4), Ewing's sarcoma (ES; 4), anaplastic astrocytoma (AA; 3), rhabdomyosarcoma (RMS; 2), ependymoma (EP; 2), cerebral primitive neuroectodermal tumor (cPNET; 2), hepatocarcinoma (HC; 1), and osteosarcoma (OS; 1).
  • CONCLUSION: Oral TMZ was well tolerated in children with resistant or relapsed solid tumors and showed activity in NB and CNS tumours refractory to standard chemotherapy.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dacarbazine / analogs & derivatives. Drug Resistance, Neoplasm. Neoplasm Recurrence, Local / drug therapy. Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Humans. Male. Survival Analysis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • [ErratumIn] Pediatr Blood Cancer. 2006 Oct 15;47(5):647-8
  • (PMID = 16047361.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


70. Lesniak MS: Gene therapy for malignant glioma. Expert Rev Neurother; 2006 Apr;6(4):479-88
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma multiforme represents the most common primary malignant tumor of the adult CNS.
  • Consequently, efforts aimed at developing new therapies have focused on new treatment strategies that specifically target tumor cells and spare normal cells.
  • One such modality, gene therapy, has shown promise in the spectrum of agents utilized against brain tumors.
  • This review highlights the principles of gene therapy and discusses the results of recent clinical trials in which gene therapy has been employed against malignant brain tumors.
  • [MeSH-major] Brain Neoplasms / genetics. Genetic Therapy / methods. Glioma / genetics

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16623647.001).
  • [ISSN] 1744-8360
  • [Journal-full-title] Expert review of neurotherapeutics
  • [ISO-abbreviation] Expert Rev Neurother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 77
  •  go-up   go-down


71. Kim HJ, Kim YJ, Seo MD, Yi HG, Lee SH, Lee SM, Kim DW, Yang SC, Lee CT, Lee JS, Kim YW, Heo DS: Patterns of palliative procedures and clinical outcomes in patients with advanced non-small cell lung cancer. Lung Cancer; 2009 Aug;65(2):242-6
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The events requiring palliative procedures were thoracic events (malignant effusion or severe pneumonia requiring intensive care unit care not related to treatment) in 32 (30%), CNS events (brain metastasis or leptomeningeal metastasis) in 37 (34%), skeletal events (bone metastasis requiring radiation, spinal cord compression, hypercalcemia) in 29 (27%), and other events in 10 (9%).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / complications. Carcinoma, Non-Small-Cell Lung / therapy. Lung Neoplasms / complications. Lung Neoplasms / therapy. Palliative Care / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19147252.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


72. Ferrari S, del Prever AB, Palmerini E, Staals E, Berta M, Balladelli A, Picci P, Fagioli F, Bacci G, Vanel D: Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma. Pediatr Blood Cancer; 2009 May;52(5):581-4
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To determine activity and toxicity of high-dose ifosfamide (HDIFO) in recurrent or advanced Ewing sarcoma family tumors (EFT).
  • RESULTS: Transient Grade 4 neutropenia and thrombocytopenia in 97% and 54% HDIFO courses respectively and severe CNS toxicity in one patient were observed.
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Male. Middle Aged. Neoplasm Staging. Recurrence

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19142994.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


73. Jeanneret-Sozzi W, Taghian A, Epelbaum R, Poortmans P, Zwahlen D, Amsler B, Villette S, Belkacémi Y, Nguyen T, Scalliet P, Maingon P, Gutiérrez C, Gastelblum P, Krengli M, Raad RA, Ozsahin M, Mirimanoff RO: Primary breast lymphoma: patient profile, outcome and prognostic factors. A multicentre Rare Cancer Network study. BMC Cancer; 2008;8:86
MedlinePlus Health Information. consumer health - Male Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Central nervous system (CNS) was the site of relapse in 12 (14%) cases.
  • Local control is excellent with RT or combined modality treatment but systemic relapses, including that in the CNS, occurs frequently.
  • [MeSH-major] Breast Neoplasms / therapy. Breast Neoplasms, Male / therapy. Lymphoma / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Mastectomy. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Radiotherapy. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 1999 Jun;26(3):357-64 [10375092.001]
  • [Cites] Ann Oncol. 2008 Feb;19(2):233-41 [17932394.001]
  • [Cites] Oncology. 2005;69(3):256-60 [16166814.001]
  • [Cites] Breast Cancer Res Treat. 2005 Oct;93(3):191-8 [16172797.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]
  • [Cites] Arch Pathol Lab Med. 1999 Dec;123(12):1208-18 [10583925.001]
  • [Cites] Am J Clin Oncol. 2000 Aug;23(4):334-6 [10955857.001]
  • [Cites] Br J Haematol. 2001 Nov;115(2):253-6 [11703318.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):6-13 [11815954.001]
  • [Cites] J Surg Oncol. 2002 May;80(1):19-25; discussion 26 [11967901.001]
  • [Cites] Ann Hematol. 2003 Jul;82(7):397-404 [12764549.001]
  • [Cites] Leuk Lymphoma. 2003 Jul;44(7):1173-8 [12916870.001]
  • [Cites] Jpn J Clin Oncol. 2003 Aug;33(8):399-403 [14523060.001]
  • [Cites] Ai Zheng. 2004 Aug;23(8):939-42 [15301719.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] Br J Cancer. 1976 Dec;34(6):585-612 [795448.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Acta Pathol Jpn. 1984 Mar;34(2):361-73 [6741549.001]
  • [Cites] Ann Surg. 1987 Feb;205(2):144-50 [3545107.001]
  • [Cites] Br J Surg. 1987 Mar;74(3):214-6 [3567516.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Oct;17(4):843-6 [2777674.001]
  • [Cites] Cancer. 1991 Mar 1;67(5):1359-69 [1991299.001]
  • [Cites] Cancer. 1992 Feb 1;69(3):725-35 [1730123.001]
  • [Cites] Am Surg. 1992 Dec;58(12):792-6 [1456611.001]
  • [Cites] Hum Pathol. 1993 Mar;24(3):274-8 [8454272.001]
  • [Cites] Am J Surg Pathol. 1993 Jun;17(6):574-87 [8333556.001]
  • [Cites] Am J Surg Pathol. 1994 Mar;18(3):288-95 [8116797.001]
  • [Cites] S Afr Med J. 1995 Feb;85(2):85-9 [7597540.001]
  • [Cites] Am J Clin Oncol. 1998 Aug;21(4):376-80 [9708637.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):25-30 [17541937.001]
  • [Cites] Haematologica. 2007 Aug;92(8):1147-8 [17650450.001]
  • [Cites] Clin Lymphoma. 2005 Jun;6(1):37-42 [15989705.001]
  • (PMID = 18380889.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2330152
  •  go-up   go-down


74. Park JH, Park EC, Park JH, Kim SG, Lee SY: Job loss and re-employment of cancer patients in Korean employees: a nationwide retrospective cohort study. J Clin Oncol; 2008 Mar 10;26(8):1302-9
MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Female sex, younger age and older age, company employee, lower income, blood cancer, and brain and CNS, lung, and liver cancer were significant predictors of early job loss or delayed re-employment.
  • [MeSH-major] Asian Continental Ancestry Group / psychology. Employment / psychology. Neoplasms / psychology. Unemployment / psychology
  • [MeSH-minor] Adult. Cohort Studies. Female. Follow-Up Studies. Humans. Korea / epidemiology. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Surveys and Questionnaires. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18323554.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


75. Olivier KR, Schild SE, Morris CG, Brown PD, Markovic SN: A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma. Cancer; 2007 Oct 15;110(8):1791-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Oncologists are often reluctant to recommend radiotherapy (RT) to palliate metastatic melanoma due to a perception that this tumor is "radioresistant."
  • METHODS: Eighty-four consecutive patients with 114 lesions that were not metastatic to the central nervous system (CNS) were evaluated for the response of the presenting symptom, the duration of response, and survival after RT.
  • CONCLUSIONS: RT was found to provide effective palliation of non-CNS metastasis from malignant melanoma and should be considered for symptomatic patients.
  • [MeSH-major] Melanoma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Skin Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Dose-Response Relationship, Radiation. Female. Humans. Male. Middle Aged. Neoplasm Staging. Palliative Care. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721993.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Sanna G, Franceschelli L, Rotmensz N, Botteri E, Adamoli L, Marenghi C, Munzone E, Cossu Rocca M, Verri E, Minchella I, Medici M, Catania C, Magni E, Goldhirsch A, Nolè F: Brain metastases in patients with advanced breast cancer. Anticancer Res; 2007 Jul-Aug;27(4C):2865-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We performed a case control study to define current features of breast cancer related to central nervous system (CNS) metastases.
  • [MeSH-major] Brain Neoplasms / secondary. Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Case-Control Studies. Cell Growth Processes / physiology. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Receptors, Estrogen / biosynthesis. Receptors, Progesterone / biosynthesis


77. Bardwell WA, Profant J, Casden DR, Dimsdale JE, Ancoli-Israel S, Natarajan L, Rock CL, Pierce JP, Women's Healthy Eating & Living (WHEL) Study Group: The relative importance of specific risk factors for insomnia in women treated for early-stage breast cancer. Psychooncology; 2008 Jan;17(1):9-18
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relative importance of specific risk factors for insomnia in women treated for early-stage breast cancer.
  • BACKGROUND: Many individual risk factors for insomnia have been identified for women with a history of breast cancer.
  • We assessed the relative importance of a wide range of risk factors for insomnia in this population.
  • METHODS: Two thousand six hundred and forty-five women < or =4 years post-treatment for Stage I (> or =1 cm)-IIIA breast cancer provided data on cancer-related variables, personal characteristics, health behaviors, physical health/symptoms, psychosocial variables, and the Women's Health Initiative-Insomnia Rating Scale (WHI-IRS; scores > or =9 indicate clinically significant insomnia).
  • RESULTS: Thirty-nine per cent had elevated WHI-IRS scores.
  • In binary logistic regression, the variance in high/low insomnia group status accounted for by each risk factor category was: cancer-specific variables, 0.4% (n.s.
  • ); personal characteristics, 0.9% (n.s.
  • ); health behaviors, 0.6% (n.s.
  • ); physical health/symptoms, 13.4% (p<0.001); and, psychosocial factors, 11.4% (p<0.001).
  • Insomnia was associated with worse depressive (OR = 1.32) and vasomotor symptoms (particularly night sweats) (OR = 1.57).
  • CONCLUSION: Various cancer-specific, demographic, health behavior, physical health, and psychosocial factors have been previously reported as risk factors for insomnia in breast cancer.
  • In our study (which was powered for simultaneous examination of a variety of variables), cancer-specific, health behavior, and other patient variables were not significant risk factors when in the presence of physical health and psychosocial variables.
  • Only worse depressive and vasomotor symptoms were meaningful predictors.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Insomnia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cornerstone. 2003;5(3):5-15 [14626537.001]
  • [Cites] Arch Intern Med. 2004 Feb 9;164(3):289-98 [14769624.001]
  • [Cites] Support Care Cancer. 2004 Mar;12(3):176-83 [14760542.001]
  • [Cites] CNS Drugs. 2004;18(5):285-96 [15089114.001]
  • [Cites] Br J Health Psychol. 2004 May;9(Pt 2):127-36 [15125800.001]
  • [Cites] Oncol Nurs Forum. 2004 May;31(3):591-5598 [15146224.001]
  • [Cites] J Clin Psychiatry. 2004;65 Suppl 8:13-9 [15153063.001]
  • [Cites] J Clin Psychiatry. 2004;65 Suppl 8:26-35 [15153065.001]
  • [Cites] J Pain Symptom Manage. 2004 Jun;27(6):513-22 [15165649.001]
  • [Cites] Biol Res Nurs. 2004 Jul;6(1):46-58 [15186707.001]
  • [Cites] Psychooncology. 2004 Sep;13(9):595-604 [15334528.001]
  • [Cites] Clin Cornerstone. 2004;6 Suppl 1B:S8-18 [15457811.001]
  • [Cites] Med Clin North Am. 2004 Nov;88(6):1575-91, xii [15464114.001]
  • [Cites] Am J Epidemiol. 1979 Feb;109(2):186-204 [425958.001]
  • [Cites] Med Care. 1988 Aug;26(8):775-89 [3398606.001]
  • [Cites] Psychosom Med. 1989 Jan-Feb;51(1):46-57 [2928460.001]
  • [Cites] J Pers Soc Psychol. 1990 May;58(5):864-77 [2348373.001]
  • [Cites] Soc Sci Med. 1991;32(6):705-14 [2035047.001]
  • [Cites] Eur Arch Psychiatry Clin Neurosci. 1993;242(6):329-36 [8323982.001]
  • [Cites] Arch Intern Med. 1994 Oct 24;154(20):2349-55 [7944857.001]
  • [Cites] J Pers Soc Psychol. 1994 Dec;67(6):1063-78 [7815302.001]
  • [Cites] Brain Res. 1995 Mar 27;675(1-2):67-74 [7796154.001]
  • [Cites] J Natl Cancer Inst. 1995 Sep 20;87(18):1372-82 [7658498.001]
  • [Cites] Sleep. 1995 Jul;18(6):425-32 [7481413.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2737-44 [7595732.001]
  • [Cites] Am Psychol. 1997 Feb;52(2):101-16 [9104085.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1380-7 [9552041.001]
  • [Cites] Maturitas. 1998 Sep 20;30(1):41-50 [9819782.001]
  • [Cites] Hosp Pract (1995). 1998 Dec 15;33(12):75-8, 83-6 [9866648.001]
  • [Cites] Sleep. 1999 May 1;22 Suppl 2:S366-72 [10394609.001]
  • [Cites] Sleep. 2004 Sep 15;27(6):1163-9 [15532211.001]
  • [Cites] Arch Intern Med. 2006 Jun 26;166(12):1262-8 [16801508.001]
  • [Cites] Oncol Nurs Forum. 2006 Jul;33(4):775-83 [16858459.001]
  • [Cites] Dialogues Clin Neurosci. 2006;8(2):217-26 [16889107.001]
  • [Cites] Alcohol Clin Exp Res. 2006 Sep;30(9):1527-37 [16930215.001]
  • [Cites] Am J Epidemiol. 2006 Sep 15;164(6):529-37 [16829553.001]
  • [Cites] Sleep Med Rev. 2006 Dec;10(6):419-29 [16963293.001]
  • [Cites] Sleep. 2000 Feb 1;23(1):41-7 [10678464.001]
  • [Cites] Psychosom Med. 2000 Mar-Apr;62(2):227-30 [10772402.001]
  • [Cites] Eur J Cancer. 2000 May;36(7):834-44 [10785587.001]
  • [Cites] Pediatrics. 2000 Aug;106(2):E23 [10920179.001]
  • [Cites] Breast J. 2002 Nov-Dec;8(6):362-70 [12390359.001]
  • [Cites] Am J Prev Med. 2004 Dec;27(5):385-90 [15556738.001]
  • [Cites] Ann Fam Med. 2004 Nov-Dec;2(6):576-82 [15576544.001]
  • [Cites] Behav Sleep Med. 2004;2(1):63-78 [15600225.001]
  • [Cites] Psychosom Med. 2005 Jan-Feb;67(1):98-104 [15673630.001]
  • [Cites] J Abnorm Psychol. 2005 Feb;114(1):111-8 [15709817.001]
  • [Cites] J Psychosom Res. 2005 Feb;58(2):183-9 [15820847.001]
  • [Cites] J Am Geriatr Soc. 2005 Jul;53(7 Suppl):S264-71 [15982375.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):6083-96 [16135475.001]
  • [Cites] Sleep. 2005 Sep;28(9):1049-57 [16268373.001]
  • [Cites] Support Care Cancer. 2005 Dec;13(12):1010-7 [15864659.001]
  • [Cites] Sleep. 2005 Jun;28(6):728-35 [16477960.001]
  • [Cites] Support Care Cancer. 2006 Mar;14(3):201-9 [16010529.001]
  • [Cites] Sleep Med. 2006 Mar;7(2):123-30 [16459140.001]
  • [Cites] Climacteric. 2006 Apr;9(2):119-28 [16698658.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2420-7 [16651649.001]
  • [Cites] Control Clin Trials. 2002 Dec;23(6):728-56 [12505249.001]
  • [Cites] J Pain Symptom Manage. 2002 Nov;24(5):471-80 [12547047.001]
  • [Cites] J Natl Cancer Inst. 2003 Feb 19;95(4):263-81 [12591983.001]
  • [Cites] Psychosom Med. 2003 Mar-Apr;65(2):259-67 [12651993.001]
  • [Cites] N Engl J Med. 2003 May 8;348(19):1839-54 [12642637.001]
  • [Cites] Psychol Assess. 2003 Jun;15(2):123-36 [12847773.001]
  • [Cites] Psychol Assess. 2003 Jun;15(2):137-48 [12847774.001]
  • [Cites] J Hum Ergol (Tokyo). 2001 Dec;30(1-2):203-9 [14564883.001]
  • [Cites] Obstet Gynecol. 2000 Sep;96(3):351-8 [10960625.001]
  • [Cites] Neuropsychobiology. 2001 Jan;43(1):54-8 [11150900.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):895-908 [11157043.001]
  • [Cites] Sleep Res Online. 2000;3(3):87-95 [11382906.001]
  • [Cites] J Stud Alcohol. 2001 May;62(3):335-43 [11414343.001]
  • [Cites] Sleep. 2001 Aug 1;24(5):583-90 [11480655.001]
  • [Cites] Clin J Pain. 2002 Mar-Apr;18(2):77-83 [11882770.001]
  • [Cites] Soc Sci Med. 2002 May;54(9):1309-21 [12058848.001]
  • [Cites] J Am Diet Assoc. 2002 Jun;102(6):801-8 [12067045.001]
  • [Cites] Psychosom Med. 2002 Sep-Oct;64(5):793-802 [12271110.001]
  • (PMID = 17428006.001).
  • [ISSN] 1057-9249
  • [Journal-full-title] Psycho-oncology
  • [ISO-abbreviation] Psychooncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA069375-09; United States / NCI NIH HHS / CA / R01 CA069375-06S1; United States / NCRR NIH HHS / RR / M01 RR000079; United States / NCI NIH HHS / CA / R01 CA069375-04S3; United States / NCI NIH HHS / CA / R01 CA069375-04S4; United States / NCI NIH HHS / CA / R01 CA069375-05S5; United States / NCRR NIH HHS / RR / M01-RR00827; United States / NCI NIH HHS / CA / R01 CA069375-06S2; United States / NCI NIH HHS / CA / R01 CA069375-05S1; United States / NCI NIH HHS / CA / R01 CA069375-03S1; United States / NCI NIH HHS / CA / R01 CA069375-04S2; United States / NCI NIH HHS / CA / R01 CA069375-08; United States / NCRR NIH HHS / RR / M01-RR00079; United States / NCI NIH HHS / CA / R01 CA069375-04; United States / NCI NIH HHS / CA / R01 CA069375-05; United States / NCI NIH HHS / CA / R01 CA069375-02; United States / NCI NIH HHS / CA / CA069375-08; United States / NCRR NIH HHS / RR / M01-RR00070; United States / NCI NIH HHS / CA / R01 CA069375-06; United States / NCI NIH HHS / CA / CA112035; United States / NCI NIH HHS / CA / R01 CA112035; United States / NCI NIH HHS / CA / R01 CA069375-10; United States / NCI NIH HHS / CA / R01 CA069375-05S4; United States / NCI NIH HHS / CA / R01 CA069375-03; United States / NCI NIH HHS / CA / R01 CA069375-07; United States / NCI NIH HHS / CA / R01 CA069375-05S2; United States / NCRR NIH HHS / RR / M01 RR000070; United States / NCI NIH HHS / CA / R01 CA069375-04S1; United States / NCRR NIH HHS / RR / M01 RR000827; United States / NCI NIH HHS / CA / R01 CA069375-02S1; United States / NCI NIH HHS / CA / R01 CA069375; United States / NCI NIH HHS / CA / CA69375; United States / NCI NIH HHS / CA / R01 CA069375-05S3
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS73982; NLM/ PMC2575103
  •  go-up   go-down


78. Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, Aldape KD, Croteau DJ, Sherman JW, Puri RK, Cintredekin Besudotox Intraparenchymal Study Group: Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol; 2007 Mar 1;25(7):837-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Glioblastoma multiforme (GBM) is a devastating brain tumor with a median survival of 6 months after recurrence.
  • PATIENTS AND METHODS: Three phase I clinical studies evaluated intracerebral CED of CB along with tumor resection.
  • All patients underwent tumor resection followed by a single intraparenchymal infusion (in addition to the intraparenchymal one following resection), with a portion of patients who had a preresection intratumoral infusion.
  • The maximum tolerated intraparenchymal concentration was 0.5 microg/mL and tumor necrosis was observed at this concentration.
  • CB- and procedure-related adverse events were primarily limited to the CNS.
  • [MeSH-major] Drug Delivery Systems / methods. Exotoxins / administration & dosage. Glioma / drug therapy. Immunotoxins / administration & dosage. Interleukin-13 / administration & dosage. Supratentorial Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Catheterization. Convection. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Tissue Distribution

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17327604.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Exotoxins; 0 / IL13-PE38QQR; 0 / Immunotoxins; 0 / Interleukin-13
  •  go-up   go-down


79. Clark JI, Moon J, Hutchins LF, Sosman JA, Kast WM, Da Silva DM, Liu PY, Thompson JA, Flaherty LE, Sondak VK: Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. Cancer; 2010 Jan 15;116(2):424-31
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One treatment-related death occurred from myocardial infarction; 3 other grade 4 events occurred, including pulmonary embolism, neutropenia, and central nervous system (CNS) ischemia.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2105-16 [10561265.001]
  • [Cites] J Clin Oncol. 2008 Dec 10;26(35):5748-54 [19001327.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):158-66 [10623706.001]
  • [Cites] Br J Cancer. 2000 Feb;82(4):812-7 [10732751.001]
  • [Cites] Am J Med. 2000 Apr 15;108(6):487-95 [10781782.001]
  • [Cites] Antimicrob Agents Chemother. 2000 Sep;44(9):2286-90 [10952569.001]
  • [Cites] Oncology (Williston Park). 2001 Jul;15(7):867-74; discussion 877-9 [11499688.001]
  • [Cites] N Engl J Med. 2001 Oct 18;345(16):1214-5 [11642248.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2736-44 [11675346.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2610-5 [12039921.001]
  • [Cites] Nat Rev Immunol. 2002 Jun;2(6):389-400 [12093005.001]
  • [Cites] J Exp Med. 2002 Aug 5;196(3):379-87 [12163566.001]
  • [Cites] Nature. 2002 Dec 5;420(6915):502-7 [12466842.001]
  • [Cites] Nat Rev Immunol. 2003 Mar;3(3):189-98 [12658267.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2551-7 [12829675.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2551-9 [12855630.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3351-6 [12947072.001]
  • [Cites] Clin Exp Immunol. 1995 Feb;99(2):160-7 [7851006.001]
  • [Cites] J Exp Med. 1998 Jun 1;187(11):1885-92 [9607928.001]
  • [Cites] J Immunol. 1999 Jul 1;163(1):380-6 [10384139.001]
  • [Cites] Melanoma Res. 2004 Dec;14(6):527-31 [15577325.001]
  • [Cites] Methods Mol Biol. 2005;302:237-52 [15937356.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2385-91 [17438097.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):527-34 [18235113.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):12643-4 [18753635.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2745-51 [10561349.001]
  • (PMID = 19918923.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / N01 CA004919; United States / NCI NIH HHS / CA / CA37981; United States / NCI NIH HHS / CA / CA58416; United States / NCI NIH HHS / CA / N01 CA035176; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / U10 CA032102-30; United States / NCI NIH HHS / CA / CA35178; United States / NCI NIH HHS / CA / CA45807; United States / NCI NIH HHS / CA / CA35261; United States / NCI NIH HHS / CA / U10 CA004919; United States / NCI NIH HHS / CA / N01 CA035431; United States / NCI NIH HHS / CA / CA22433; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / U10 CA045560; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / N01 CA032102; United States / NCI NIH HHS / CA / CA76426; United States / NCI NIH HHS / CA / U10 CA045808; United States / NCI NIH HHS / CA / N01 CA045807; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / U10 CA074647; United States / NCI NIH HHS / CA / CA11083; United States / NCI NIH HHS / CA / CA58861; United States / NCI NIH HHS / CA / K24 CA097588; United States / NCI NIH HHS / CA / CA46282; United States / NCI NIH HHS / CA / U10 CA035261; United States / NCI NIH HHS / CA / U10 CA035178; United States / NCI NIH HHS / CA / U10 CA045461; United States / NCI NIH HHS / CA / U10 CA032102; United States / NCI NIH HHS / CA / U10 CA046282; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / N01 CA035178; United States / NCI NIH HHS / CA / N01 CA038926; United States / NCI NIH HHS / CA / CA032102-30; United States / NCI NIH HHS / CA / CA45461; United States / NCI NIH HHS / CA / U10 CA067575; United States / NCI NIH HHS / CA / CA74647; United States / NCI NIH HHS / CA / U10 CA020319; United States / NCI NIH HHS / CA / U10 CA038926; United States / NCI NIH HHS / CA / CA35176; United States / NCI NIH HHS / CA / U10 CA035431; United States / NCI NIH HHS / CA / U10 CA011083; United States / NCI NIH HHS / CA / N01 CA067575; United States / NCI NIH HHS / CA / CA04919; United States / NCI NIH HHS / CA / U10 CA035176; United States / NCI NIH HHS / CA / CA67575; United States / NCI NIH HHS / CA / U10 CA045807; United States / NCI NIH HHS / CA / N01 CA045560
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Other-IDs] NLM/ NIHMS151995; NLM/ PMC2811758
  •  go-up   go-down


80. Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT: Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol; 2009 Nov 20;27(33):5601-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • End points included response rate (via Response Evaluation Criteria in Solid Tumors [RECIST] or modified Gynecological Cancer Intergroup CA-125), toxicity, progression-free survival (PFS), and overall survival (OS).
  • Grade 4 toxicities included CNS hemorrhage (n = 1), hypertriglyceridemia/hypercholesterolemia/elevated lipase (n = 1), and dehydration/elevated creatinine (n = 1).
  • [MeSH-major] Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasms, Glandular and Epithelial / drug therapy. Quinazolines / administration & dosage. Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
  • [MeSH-minor] Administration, Oral. Adult. Aged. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Fallopian Tube Neoplasms / drug therapy. Fallopian Tube Neoplasms / mortality. Fallopian Tube Neoplasms / pathology. Female. Humans. Maximum Tolerated Dose. Middle Aged. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / mortality. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / mortality. Peritoneal Neoplasms / pathology. Prognosis. Risk Assessment. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Fallopian Tube Cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] J Natl Cancer Inst. 2002 Jun 5;94(11):819-25 [12048269.001]
  • [Cites] Eur J Cancer. 1991;27(11):1367-72 [1835850.001]
  • [Cites] N Engl J Med. 1996 Jan 4;334(1):1-6 [7494563.001]
  • [Cites] J Clin Oncol. 1996 Jun;14(6):1895-902 [8656258.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4389-400 [15899831.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5018-22 [16951216.001]
  • [Cites] Nat Rev Cancer. 2007 Jun;7(6):475-85 [17522716.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3045-54 [17634482.001]
  • [Cites] J Clin Oncol. 2007 Nov 20;25(33):5165-71 [18024863.001]
  • [Cites] J Clin Oncol. 2007 Nov 20;25(33):5180-6 [18024865.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Clin Oncol. 2008 Apr 10;26(11):1871-8 [18398152.001]
  • [Cites] N Engl J Med. 2008 May 8;358(19):2039-49 [18463380.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4754-62 [18559522.001]
  • [Cites] N Engl J Med. 2009 Feb 5;360(6):563-72 [19196673.001]
  • [Cites] Ann Oncol. 2009 Feb;20(2):227-30 [18842611.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1534-5 [10995813.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):487-8 [15026475.001]
  • (PMID = 19826113.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinazolines; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; NQU9IPY4K9 / cediranib
  • [Other-IDs] NLM/ PMC2792954
  •  go-up   go-down


81. Grossman SA, Alavi JB, Supko JG, Carson KA, Priet R, Dorr FA, Grundy JS, Holmlund JT: Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas. Neuro Oncol; 2005 Jan;7(1):32-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aprinocarsen is an antisense oligonucleotide against PKC-alpha that reduces PKC-alphain human cell lines and inhibits a human glioblastoma tumor cell line in athymic mice.
  • Their median age was 46 years (range, 28-68 years), median Karnofsky performance status was 80 (range, 60-100), median tumor volume was 58 cm3 (range, 16-254 cm3), and histology included glioblastoma multiforme (n = 16), anaplastic oligodendroglioma (n = 4), and anaplastic astrocytoma (n = 1).
  • No tumor responses were observed.
  • The observed toxicities were mild, reversible, and uncommon (grade 3 thrombocytopenia [n = 3] and grade 4 AST [n = 1]), and no coagulopathy or CNS bleeding resulted from this therapy.
  • The rapid deterioration seen in these patients could result from tumor growth or an effect of aprinocarsen on bloodbrain barrier integrity.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Pharmacol. 1996 Aug;50(2):236-42 [8700129.001]
  • [Cites] Glia. 1999 Feb 1;25(3):240-6 [9932870.001]
  • [Cites] J Biopharm Stat. 1997 Mar;7(1):171-8 [9056596.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3121-8 [9294475.001]
  • [Cites] J Biol Chem. 1998 Mar 13;273(11):6001-4 [9497312.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3586-95 [10550158.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3357-63 [10589745.001]
  • [Cites] Prog Neurobiol. 2001 Feb;63(3):321-36 [11115728.001]
  • [Cites] Curr Oncol Rep. 2000 Sep;2(5):445-53 [11122877.001]
  • [Cites] Neurosci Lett. 2001 Jan 19;297(3):163-6 [11137753.001]
  • [Cites] Brain Res Mol Brain Res. 2001 Nov 1;95(1-2):110-6 [11687282.001]
  • [Cites] Curr Oncol Rep. 2002 Jan;4(1):37-46 [11734112.001]
  • [Cites] Expert Opin Investig Drugs. 2001 Dec;10(12):2117-40 [11772309.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2002 Feb;72(2):262-5 [11796780.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1042-8 [11948111.001]
  • [Cites] Neurosci Lett. 2002 May 17;324(2):105-8 [11988338.001]
  • [Cites] Am J Physiol Renal Physiol. 2002 Aug;283(2):F309-18 [12110515.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2188-92 [12114419.001]
  • [Cites] J Anat. 2002 Jun;200(6):617-27 [12162729.001]
  • [Cites] J Anat. 2002 Jun;200(6):639-46 [12162731.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):96-103 [12672281.001]
  • [Cites] Lancet Neurol. 2003 Jul;2(7):404-9 [12849118.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2940-9 [12912940.001]
  • [Cites] J Pharm Sci. 1985 Feb;74(2):229-31 [3989700.001]
  • [Cites] Chem Pharm Bull (Tokyo). 1985 Apr;33(4):1620-32 [4042238.001]
  • [Cites] Biochem Biophys Res Commun. 1987 Oct 29;148(2):718-25 [3689368.001]
  • [Cites] Nature. 1988 Aug 25;334(6184):661-5 [3045562.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Cancer Res. 1989 Jun 15;49(12):3215-7 [2720675.001]
  • [Cites] Biochem Biophys Res Commun. 1989 Sep 29;163(3):1377-83 [2783141.001]
  • [Cites] Cancer Res. 1990 Feb 1;50(3):677-85 [2297708.001]
  • [Cites] Br J Cancer. 1992 Jul;66(1):10-9 [1637658.001]
  • [Cites] Pharmacol Ther. 1993 Sep;59(3):257-80 [8309991.001]
  • [Cites] J Biol Chem. 1994 Jun 10;269(23):16416-24 [7911467.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11762-6 [7972137.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;42(2):118-26 [9654111.001]
  • [Cites] Anal Biochem. 1996 Mar 1;235(1):36-43 [8850544.001]
  • (PMID = 15701280.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062475; United States / NCI NIH HHS / CA / U01-CA-26406; United States / NCI NIH HHS / CA / UO1CA-62475
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Oligonucleotides, Antisense; 0 / Phosphorothioate Oligonucleotides; EC 2.7.11.13 / PRKCA protein, human; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / Protein Kinase C-alpha; FMT95051CQ / aprinocarsen
  • [Other-IDs] NLM/ PMC1871621
  •  go-up   go-down


82. D'Haene N, Coen N, Neugroschl C, Balériaux D, Salmon I: Leptomeningeal dissemination of low-grade intramedullary gliomas: about one case and review. Clin Neurol Neurosurg; 2009 May;111(4):390-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we report a case of an intramedullary spinal cord low-grade glioma occurring in an adult presenting by LM dissemination.
  • Lumbar puncture showed low CSF glucose, high CSF protein and no tumor cells.
  • Histological examination revealed a low-grade glial neoplasm composed of monomorphous spindle "piloid" cells with diffuse dissemination to leptomeninges.
  • This case, like cases occurring in children, cannot easily be classified in the present WHO system of classification of CNS tumors.
  • [MeSH-major] Glioma / secondary. Meningeal Neoplasms / secondary. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19128871.001).
  • [ISSN] 1872-6968
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 24
  •  go-up   go-down


83. Bavaresco L, Bernardi A, Braganhol E, Wink MR, Battastini AM: Dexamethasone inhibits proliferation and stimulates ecto-5'-nucleotidase/CD73 activity in C6 rat glioma cell line. J Neurooncol; 2007 Aug;84(1):1-8
Hazardous Substances Data Bank. ADENOSINE 5'-PHOSPHATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant gliomas are the most common and devastating primary tumors of the adult central nervous system.
  • Dexamethasone, a synthetic glucocorticoid, is commonly co-administered to control edema in the management of brain tumors during chemotherapy and radiotherapy.
  • [MeSH-major] 5'-Nucleotidase / metabolism. Anti-Inflammatory Agents / pharmacology. Brain Neoplasms / enzymology. Dexamethasone / pharmacology. Glioma / enzymology
  • [MeSH-minor] Adenosine Monophosphate / metabolism. Animals. Cell Death / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Protein Kinase C / metabolism. Purines / metabolism. Rats. Signal Transduction / drug effects. Time Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17453149.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Purines; 415SHH325A / Adenosine Monophosphate; 7S5I7G3JQL / Dexamethasone; EC 2.7.11.13 / Protein Kinase C; EC 3.1.3.5 / 5'-Nucleotidase
  •  go-up   go-down


84. Gore SD, Gojo I, Sekeres MA, Morris L, Devetten M, Jamieson K, Redner RL, Arceci R, Owoeye I, Dauses T, Schachter-Tokarz E, Gallagher RE: Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J Clin Oncol; 2010 Feb 20;28(6):1047-53
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thirty-seven patients received consolidation and maintenance; of these one patient relapsed (CNS) and one died in remission during maintenance therapy (hepatic sickle cell crisis).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Arsenicals / administration & dosage. Child. Child, Preschool. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Staging. Oxides / administration & dosage. Prognosis. Remission Induction. Survival Rate. Treatment Outcome. Tretinoin / administration & dosage. Young Adult


85. Mohile NA, Deangelis LM, Abrey LE: The utility of body FDG PET in staging primary central nervous system lymphoma. Neuro Oncol; 2008 Apr;10(2):223-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The utility of body FDG PET in staging primary central nervous system lymphoma.
  • (18)F-Fluorodeoxyglucose (FDG) PET has become an important tool in the management of non-Hodgkin's lymphoma (NHL), but its role in the evaluation of primary CNS lymphoma (PCNSL) has not been established.
  • NHL was found in 11% of all patients, 7% of patients at diagnosis, and 27% of patients at CNS relapse.
  • Four percent had a second systemic neoplasm.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Central Nervous System Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Lymphoma / pathology. Lymphoma / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 1999 Jul;43(3):231-6 [10563428.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):571-8 [17242397.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):414-9 [11208833.001]
  • [Cites] Br J Haematol. 2001 Dec;115(4):793-800 [11843811.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Mar;31(3):325-9 [14647988.001]
  • [Cites] Cancer. 1989 Mar 1;63(5):939-47 [2914300.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):635-43 [1548527.001]
  • [Cites] J Neurooncol. 1995;25(1):67-71 [8523091.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4643-51 [15837966.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4577-80 [15837974.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5034-43 [15955902.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Aug;19(4):611-27, v [16083826.001]
  • [Cites] Nucl Med Commun. 2006 Jan;27(1):11-5 [16340718.001]
  • [Cites] N Engl J Med. 2006 Feb 2;354(5):496-507 [16452561.001]
  • [Cites] Haematologica. 2006 Apr;91(4):522-9 [16585017.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4754-7 [16966685.001]
  • [Cites] J Neurooncol. 2006 Nov;80(2):159-65 [16699873.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):11055-61 [17108145.001]
  • [Cites] Ann Hematol. 2007 Jan;86(1):9-15 [17021839.001]
  • [Cites] Br J Radiol. 2000 May;73(869):482-7 [10884743.001]
  • (PMID = 18287338.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC2613825
  •  go-up   go-down


86. Eyenga VC, Ngah JE, Atangana R, Etom E, Ngowe MN, Bassong Y, Oyono JL, Sosso M: [Central nervous system tumours in Cameroon: histopathology and demography]. Sante; 2008 Jan-Mar;18(1):39-42
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Central nervous system tumours in Cameroon: histopathology and demography].
  • [Transliterated title] Les tumeurs du système nerveux central au Cameroun: histopathologie, démographie.
  • Tumours of the central nervous system (CNS) have not received much scientific attention in sub-Saharan Africa, especially in the central African zone.
  • The aim of this study was to determine the relative frequency and different histologic types of CNS tumours seen in the neurosurgery units of Cameroon, a multiethnic country of central Africa.
  • This retrospective study covers the decade from January 1996 through December 2006 in the three neurosurgery departments in Cameroon, at the Yaoundé General Hospital, the Yaoundé Central Hospital, and the Douala General Hospital.
  • INCLUSION CRITERIA: All cases undergoing surgery in these units for a histologically-confirmed CNS tumour.
  • The average age of patients with metastatic tumors was 42+/-18.5 years compared with 36.5+/-17.8 years for cases with primary tumors.
  • Primary tumors were malignant in 34.2% (n=12) of the children and benign in 65.8% (n=23); among adults 22.7% (n=30) were malignant and 77.3% (n=102) benign.
  • In conclusion, CNS tumors occurred mainly before the age of 55 years and had a slight predilection for girls and women.
  • Meningiomas were the most frequent tumors in adults while astrocytomas were more prevalent in children.
  • [MeSH-major] Brain Neoplasms / epidemiology. Meningeal Neoplasms / epidemiology. Meningioma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Astrocytoma / epidemiology. Astrocytoma / pathology. Brain / pathology. Cameroon. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Meninges / pathology. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18684690.001).
  • [ISSN] 1157-5999
  • [Journal-full-title] Santé (Montrouge, France)
  • [ISO-abbreviation] Sante
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


87. Puente Vázquez J, López-Tarruella Cobo S, García-Sáenz JA, Casado Herráez A, Moreno Antón F, Sampedro Gimeno T, Bueno Muiño C, Grande Pulido E, Martín Jiménez M, Díaz-Rubio E: Brain metastases in metastatic breast cancer patients receiving trastuzumab-based therapies. Clin Transl Oncol; 2006 Jan;8(1):50-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: CNS metastases mean a great challenge.
  • RESULTS: CNS progression occurred in 17 patients (19.5%).
  • Mean age of CNS progression disease patients was 45.4 years while mean age for all the patients was 50.5 years.
  • Response rate to trastuzumab based-therapy was OR 82.4% and CB 88.2 at the time of CNS progression.
  • Median time from the start of trastuzumab therapy up to the CNS progression was 10 months.
  • CONCLUSIONS: The incidence of CNS involvement is high in young metastasic breast cancer women responding to trastuzumab-based therapies.
  • [MeSH-major] Adenocarcinoma / secondary. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Brain Neoplasms / secondary. Breast Neoplasms / drug therapy. Carcinoma / secondary
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Cranial Irradiation. Disease Progression. Female. Humans. Incidence. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Proteins / antagonists & inhibitors. Receptor, Epidermal Growth Factor / analysis. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, ErbB-4. Retrospective Studies. Survival Analysis. Trastuzumab. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16632440.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Neoplasm Proteins; EC 2.7.10.1 / ERBB4 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-4; P188ANX8CK / Trastuzumab
  •  go-up   go-down


88. Bariakh EA, Kravchenko SK, Kremenetskaia AM, Zvonkov EE, Obukhova TN, Magomedova AU, Vorob'ev AI: [Clinical and epidemiological features of Burkitt's lymphoma]. Ter Arkh; 2009;81(7):47-53
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To characterize clinical and epidemiological features of adult Berkitt's lymphoma (BL).
  • Bone marrow involvement was diagnosed in 22 (31%) patients, CNS was affected in 17 (24%) patients, of them 14 were males.
  • Fifty two (72%) patients had abdominal, retroperitoneal and/or small pelvis tumors.
  • Intestinal, hepatic, renal and gastric tumors occurred most frequently.
  • Specific ascitis was detected in 25 (48%), tumor pleuritis--in 11 (15%) patients.
  • Seven patients had concomitant involvement of the CNS.
  • Eight (38%) and 2 (10%) women had tumors of the ovaries and uterus, respectively.
  • CONCLUSION: BL is characterized by the following clinical features: young age of the patients, most of them are males, B-symptoms, short history, generalized stages, extranodal lesions, firequent involvement of the bone marrow and CNS.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Female. Humans. L-Lactate Dehydrogenase / metabolism. Male. Middle Aged. Neoplasm Staging. Sex Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19708573.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


89. Simon T, Kohlhase J, Wilhelm C, Kochanek M, De Carolis B, Berthold F: Multiple malignant diseases in a patient with Rothmund-Thomson syndrome with RECQL4 mutations: Case report and literature review. Am J Med Genet A; 2010 Jun;152A(6):1575-9
SciCrunch. Clinical Genomic Database: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most remarkable clinical features are young age, spontaneous remission of diffuse large cell lymphoma, and severe CNS and skin toxicity of cytotoxic treatment.
  • [MeSH-major] Bone Neoplasms / genetics. Leukemia, Large Granular Lymphocytic / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Osteosarcoma / genetics. RecQ Helicases / genetics. Rothmund-Thomson Syndrome / genetics
  • [MeSH-minor] Fatal Outcome. Heterozygote. Humans. Male. Mutation. Neoplasm Regression, Spontaneous. Young Adult


90. Eralp Y, Saip P, Aydin Z, Berkman S, Topuz E: Leptomeningeal dissemination of ovarian carcinoma through a ventriculoperitoneal shunt. Gynecol Oncol; 2008 Jan;108(1):248-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Dissemination of ovarian cancer occurs mainly within the peritoneal cavity and central nervous system involvement (CNS) is encountered rarely.
  • [MeSH-major] Meningeal Neoplasms / secondary. Neoplasm Seeding. Ovarian Neoplasms / pathology. Ventriculoperitoneal Shunt / adverse effects
  • [MeSH-minor] Adult. Female. Humans. Hydrocephalus / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961641.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Cagayan MS, Lu-Lasala LR: Management of gestational trophoblastic neoplasia with metastasis to the central nervous system: A 12-year review at the Philippine General Hospital. J Reprod Med; 2006 Oct;51(10):785-92
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of gestational trophoblastic neoplasia with metastasis to the central nervous system: A 12-year review at the Philippine General Hospital.
  • Of the 30 patients, 17 (56.7%) belonged to the "early" group (having central nervous system [CNS] symptoms on presentation), while 13 (43.3%) were in the "late" group (individuals who developed lesions during chemotherapy or who had relapsed after initial complete or partial remission).
  • The mean survival time for the early CNS group was 7.3 months; it was 8.3 months for the late CNS group.
  • [MeSH-major] Central Nervous System Neoplasms / epidemiology. Gestational Trophoblastic Disease / epidemiology. Uterine Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Injections, Spinal. Medical Records. Methotrexate / administration & dosage. Middle Aged. Neoplasm Metastasis. Philippines / epidemiology. Pregnancy. Retrospective Studies. Survival Analysis. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17086807.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate; EMA-CO protocol
  •  go-up   go-down


92. Safwat A, Schmidt H, Bastholt L, Fode K, Larsen S, Aggerholm N, von der Maase H: A phase II trial of low-dose total body irradiation and subcutaneous interleukin-2 in metastatic melanoma. Radiother Oncol; 2005 Nov;77(2):143-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The dose was modified in 15 cycles (26%) because of progression (6), liver toxicity (3), CNS toxicity (2), thrombocytopenia (1), lung morbidity (1) and itching (1).
  • [MeSH-major] Interleukin-2 / therapeutic use. Melanoma / secondary. Melanoma / therapy. Skin Neoplasms / pathology. Skin Neoplasms / therapy. Whole-Body Irradiation / methods
  • [MeSH-minor] Adult. Aged. Denmark. Dose-Response Relationship, Drug. Dose-Response Relationship, Radiation. Female. Flow Cytometry. Follow-Up Studies. Humans. Injections, Subcutaneous. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Radiotherapy Dosage. Risk Assessment. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16216360.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Interleukin-2
  •  go-up   go-down


93. Schor NF: Pharmacotherapy for adults with tumors of the central nervous system. Pharmacol Ther; 2009 Mar;121(3):253-64
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacotherapy for adults with tumors of the central nervous system.
  • Tumors of the adult central nervous system are among the most common and most chemoresistant neoplasms.
  • Malignant tumors of the brain and spinal cord collectively account for approximately 1.3% of all cancers and 2.2% of all cancer-related deaths.
  • Novel pharmacological approaches to nervous system tumors are urgently needed.
  • This review presents the current approaches and challenges to successful pharmacotherapy of adults with malignant tumors of the central nervous system and discusses novel approaches aimed at overcoming these challenges.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Relat Cancer. 2008 Sep;15(3):721-43 [18753362.001]
  • [Cites] J Neurooncol. 2002 Jun;58(2):115-23 [12164682.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2725-34 [12171906.001]
  • [Cites] Anticancer Res. 2002 Jul-Aug;22(4):2029-36 [12174880.001]
  • [Cites] Cancer. 2002 Sep 1;95(5):1113-9 [12209698.001]
  • [Cites] Chemotherapy. 2002 Sep;48(4):189-95 [12218266.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):3008-18 [12231548.001]
  • [Cites] Glia. 2002 Oct;40(1):44-54 [12237842.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Dec;50(6):479-89 [12451475.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] Ann Oncol. 2003 Apr;14(4):599-602 [12649108.001]
  • [Cites] Neuroimaging Clin N Am. 2002 Nov;12(4):525-36 [12687909.001]
  • [Cites] Neuroimaging Clin N Am. 2002 Nov;12(4):583-97 [12687913.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2B):1631-5 [12820433.001]
  • [Cites] Curr Opin Oncol. 2003 Nov;15(6):412-8 [14624222.001]
  • [Cites] Clin Cancer Res. 2004 Dec 1;10(23):7875-83 [15585620.001]
  • [Cites] Lancet Neurol. 2005 Jan;4(1):4-5 [15620846.001]
  • [Cites] J Neurol Sci. 2005 Feb 15;228(2):143-7 [15694195.001]
  • [Cites] J Neurooncol. 2005 Feb;71(3):295-9 [15735920.001]
  • [Cites] J Neurooncol. 2005 Feb;71(3):301-5 [15735921.001]
  • [Cites] Anticancer Res. 2004 Nov-Dec;24(6):4195-203 [15736473.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2411-22 [15800333.001]
  • [Cites] Neurology. 2005 Apr 26;64(8):1444-5 [15851741.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):880-7 [15956649.001]
  • [Cites] Front Biosci. 2005;10:2645-68 [15970525.001]
  • [Cites] Eur J Endocrinol. 2005 Jul;153(1):135-41 [15994755.001]
  • [Cites] J Neurosurg. 2005 Jun;102(6):1170; author reply 1170-1 [16028784.001]
  • [Cites] Oncogene. 2005 Aug 4;24(33):5226-34 [15897911.001]
  • [Cites] Neurochem Int. 2005 Nov;47(6):430-41 [16087277.001]
  • [Cites] Mol Cancer Ther. 2005 Sep;4(9):1293-302 [16170020.001]
  • [Cites] J Neurooncol. 2005 Sep;74(2):113-21 [16193381.001]
  • [Cites] Cancer Lett. 2006 Jan 8;231(1):74-86 [16356833.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11419-28 [16357150.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):172-9 [16323194.001]
  • [Cites] Pituitary. 2005;8(1):43-52 [16411068.001]
  • [Cites] Pituitary. 2005;8(1):53-60 [16411069.001]
  • [Cites] BMC Cancer. 2006;6:2 [16393339.001]
  • [Cites] Eur J Endocrinol. 2006 Mar;154(3):467-77 [16498061.001]
  • [Cites] Eur Spine J. 2006 Feb;15(2):203-10 [16374649.001]
  • [Cites] J Endocrinol Invest. 2006 Jan;29(1):86-93 [16553040.001]
  • [Cites] J Cell Physiol. 2006 Jul;208(1):220-8 [16575905.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4687-92 [16651420.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12(9):2716-29 [16675563.001]
  • [Cites] Neurosurg Focus. 2006;20(4):E22 [16709028.001]
  • [Cites] Neurosurg Focus. 2006;20(4):E24 [16709030.001]
  • [Cites] Neurosurg Focus. 2006;20(4):E7 [16709038.001]
  • [Cites] Cell Death Differ. 2006 Jul;13(7):1238-41 [16456578.001]
  • [Cites] Oncol Rep. 2006 Jul;16(1):127-32 [16786135.001]
  • [Cites] Front Horm Res. 2006;35:129-34 [16809928.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 Jul;6(7):1087-104 [16831080.001]
  • [Cites] Endocr Rev. 2006 Aug;27(5):485-534 [16705142.001]
  • [Cites] Anticancer Drugs. 2006 Aug;17(7):733-51 [16926624.001]
  • [Cites] Nat Clin Pract Neurol. 2005 Dec;1(2):88-95 [16932504.001]
  • [Cites] BMC Complement Altern Med. 2006;6:27 [16914050.001]
  • [Cites] J Neurooncol. 2006 Sep;79(3):271-9 [16645721.001]
  • [Cites] Glia. 2006 Dec;54(8):850-60 [16981197.001]
  • [Cites] Int J Oncol. 2006 Nov;29(5):1295-301 [17016664.001]
  • [Cites] Oncol Rep. 2006 Nov;16(5):1117-21 [17016602.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Oct;2(10):552-61 [17024154.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Dec;319(3):1424-34 [16971507.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 Nov;6(11):1585-92 [17134363.001]
  • [Cites] NMR Biomed. 2006 Dec;19(8):1035-42 [16894643.001]
  • [Cites] Jpn J Clin Oncol. 2008 May;38(5):373-80 [18413337.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Sep;62(4):699-706 [18338171.001]
  • [Cites] Neurology. 2008 Jul 29;71(5):365-73 [18663182.001]
  • [Cites] J Neurooncol. 2003 Oct;65(1):77-85 [14649887.001]
  • [Cites] Pituitary. 2003;6(1):19-27 [14674720.001]
  • [Cites] Lancet Oncol. 2004 Feb;5(2):89-100 [14761812.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):807-13 [14770438.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):927-31 [14967452.001]
  • [Cites] Clin Neuropathol. 2004 Jan-Feb;23(1):21-7 [14986930.001]
  • [Cites] J Neurooncol. 2004 Feb;66(3):365-75 [15015670.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1712-6 [15073861.001]
  • [Cites] Neuroendocrinology. 2004 Mar;79(3):142-8 [15103227.001]
  • [Cites] Neurosurg Focus. 2003 Nov 15;15(5):E13 [15323470.001]
  • [Cites] J Exp Clin Cancer Res. 2004 Jun;23(2):201-6 [15354403.001]
  • [Cites] Neurology. 2004 Sep 14;63(5):901-3 [15365145.001]
  • [Cites] Neurology. 2004 Sep 14;63(5):904-6 [15365146.001]
  • [Cites] Mol Cancer Ther. 2004 Sep;3(9):1127-35 [15367707.001]
  • [Cites] J Neurosurg. 2004 Oct;101(4):653-8 [15481721.001]
  • [Cites] J Neurosurg. 2004 Nov;101(5):826-31 [15540922.001]
  • [Cites] J Inorg Biochem. 2004 Dec;98(12):2168-73 [15541507.001]
  • [Cites] BMC Cancer. 2006;6:294 [17181871.001]
  • [Cites] J Clin Neurosci. 2007 Mar;14(3):261-6 [17258135.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):960-9 [17342095.001]
  • [Cites] Clin Neurosurg. 2006;53:345-51 [17380773.001]
  • [Cites] Curr Pharm Biotechnol. 2007 Apr;8(2):105-13 [17430159.001]
  • [Cites] J Natl Cancer Inst. 2007 Apr 18;99(8):639-52 [17440165.001]
  • [Cites] Ann Neurol. 2007 May;61(5):484-90 [17469128.001]
  • [Cites] J Mol Med (Berl). 2007 May;85(5):497-509 [17221219.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4467-73 [17483362.001]
  • [Cites] Neurology. 2007 May 22;68(21):1831-6 [17515545.001]
  • [Cites] J Neurochem. 2007 Jul;102(2):522-38 [17596214.001]
  • [Cites] Ann Endocrinol (Paris). 2007 Jun;68(2-3):118-9 [17512893.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12867-72 [17646646.001]
  • [Cites] Mol Cancer Ther. 2007 Aug;6(8):2290-302 [17699724.001]
  • [Cites] Neurol Med Chir (Tokyo). 2007 Aug;47(8):341-9; discussion 350 [17721049.001]
  • [Cites] J Neurooncol. 2007 Oct;85(1):1-10 [17429576.001]
  • [Cites] Bull Cancer. 2007 Sep;94(9):769-73 [17878096.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):643-53 [10690550.001]
  • [Cites] Acta Neuropathol. 2000 May;99(5):555-62 [10805101.001]
  • [Cites] J Clin Neurosci. 2000 Jan;7(1):20-3 [10847645.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jun;85(6):2247-52 [10852458.001]
  • [Cites] J Neurooncol. 2000;46(2):157-71 [10894369.001]
  • [Cites] Int J Oncol. 2000 Sep;17(3):501-5 [10938390.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] Ann Endocrinol (Paris). 2000 Nov;61(5):411-7 [11084391.001]
  • [Cites] Cancer Treat Rev. 2000 Dec;26(6):449-62 [11139374.001]
  • [Cites] J Exp Clin Cancer Res. 2000 Sep;19(3):357-62 [11144529.001]
  • [Cites] Neurosurgery. 2001 Jan;48(1):151-7 [11152340.001]
  • [Cites] J Neurooncol. 2000 Sep;49(2):105-15 [11206006.001]
  • [Cites] J Neurooncol. 2000 Sep;49(2):117-29 [11206007.001]
  • [Cites] Jpn J Cancer Res. 2001 Feb;92(2):211-9 [11223551.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jan;86(1):140-5 [11231991.001]
  • [Cites] J Neurooncol. 2000 Dec;50(3):227-37 [11263502.001]
  • [Cites] Eur J Cancer. 2001 May;37(7):930-8 [11313183.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Aug;86(8):3809-14 [11502816.001]
  • [Cites] Cancer Gene Ther. 2001 Aug;8(8):589-98 [11571537.001]
  • [Cites] Br J Cancer. 2001 Sep 28;85(7):1077-83 [11592782.001]
  • [Cites] J Neuroimmunol. 2001 Nov 1;120(1-2):19-24 [11694315.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Nov;86(11):5256-61 [11701688.001]
  • [Cites] Curr Opin Neurol. 2001 Dec;14(6):679-82 [11723373.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):552-60 [11905710.001]
  • [Cites] Neurology. 2002 Apr 23;58(8):1310-1 [11971113.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2277-83 [11980998.001]
  • [Cites] Med Oncol. 2002;19(1):1-9 [12025885.001]
  • [Cites] Expert Opin Investig Drugs. 2002 Jun;11(6):787-800 [12036422.001]
  • [Cites] Lancet Oncol. 2002 Jul;3(7):397-406 [12142169.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4307-15 [12154034.001]
  • (PMID = 19091301.001).
  • [ISSN] 0163-7258
  • [Journal-full-title] Pharmacology & therapeutics
  • [ISO-abbreviation] Pharmacol. Ther.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS038569; United States / NINDS NIH HHS / NS / NS038569-10; United States / NCI NIH HHS / CA / CA074289-09; United States / NCI NIH HHS / CA / R01 CA074289-09; United States / NCI NIH HHS / CA / R01 CA074289; United States / NINDS NIH HHS / NS / R01 NS038569-10
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 132
  • [Other-IDs] NLM/ NIHMS103661; NLM/ PMC2782733
  •  go-up   go-down


94. Bertalanffy A, Roessler K, Koperek O, Gelpi E, Prayer D, Knosp E: Recurrent central neurocytomas. Cancer; 2005 Jul 1;104(1):135-42
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent central neurocytomas.
  • BACKGROUND: Since the first description of Central neurocytomas (CNs) as a benign tumor entity in 1982, there has been great enthusiasm regarding the benign course and the curative surgical approach to this disease.
  • RESULTS: Between 1985-2003. surgical resection was performed in 14 patients with CNs ages 16-43 years (7 were female and 7 were male).
  • The MIB-1 proliferation index ranged from 0.8-11% (median of 4.6%), but was reported to be 46.8% in the malignant transformed tumor.
  • CONCLUSIONS: CNs appear to have a higher tendency to recur during long-term follow-up than previously reported, even after complete resection.
  • [MeSH-major] Brain Neoplasms / epidemiology. Neoplasm Recurrence, Local / epidemiology. Neurocytoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Female. Follow-Up Studies. Humans. Male. Retrospective Studies. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15880432.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


95. Vu BA, Duvic M: Central nervous system involvement in patients with mycosis fungoides and cutaneous large-cell transformation. J Am Acad Dermatol; 2008 Aug;59(2 Suppl 1):S16-22
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system involvement in patients with mycosis fungoides and cutaneous large-cell transformation.
  • Central nervous system (CNS) involvement in mycosis fungoides (MF) is a rare occurrence with devastating consequences.
  • In this report, we present 5 patients with MF, LCT, and CNS disease to better define their presentation, treatment, and prognosis and present critical differences they have compared with their nontransformed counterparts.
  • We found that patients with LCT and MF are at increased risk of CNS involvement.
  • In addition, whereas patients with nontransformed MF typically have significant skin and visceral involvement at the time of CNS disease, some patients with LCT have no extracutaneous symptoms and their skin MF is in remission at the time of CNS presentation.
  • Therefore, we recommend at least annual screening of patients with transformed MF for CNS disease with head computerized tomography with orbital cuts.
  • [MeSH-major] Cell Transformation, Neoplastic. Central Nervous System Neoplasms / pathology. Mycosis Fungoides / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Fatal Outcome. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Prognosis

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18625371.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Castro-Rebollo M, Vleming EN, Drake-Rodríguez P, Benítez-Herreros J, Pérez-Rico C: [Primary cerebral lymphoma diagnosed by the ophthalmologist]. Arch Soc Esp Oftalmol; 2010 Jan;85(1):35-7
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The biopsy confirmed the diagnosis of lymphoid neoplasm.
  • DISCUSSION: Primary lymphoma is the most common malignancy of the central nervous system (CNS) in AIDS patients, although highly active antiretroviral therapy has reduced its incidence.
  • The ophthalmologist plays an essential role in the diagnosis of CNS neoplasm.
  • [MeSH-major] Brain Neoplasms / diagnosis. Lymphoma / diagnosis. Parietal Lobe
  • [MeSH-minor] Humans. Male. Ophthalmology. Papilledema / etiology. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20566168.001).
  • [ISSN] 1989-7286
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


97. Liang KL, Jiang RS, Lin JC, Chiu YJ, Shiao JY, Su MC, Hsin CH: Central nervous system infection in patients with postirradiated nasopharyngeal carcinoma: a case-controlled study. Am J Rhinol Allergy; 2009 Jul-Aug;23(4):417-21
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system infection in patients with postirradiated nasopharyngeal carcinoma: a case-controlled study.
  • BACKGROUND: It has been assumed that postirradiated nasopharyngeal carcinoma (NPC) patients are prone to central nervous system (CNS) infection.
  • METHODS: From September 1989 to May 2006, we conducted a retrospective study of 18 postirradiated NPC patients with CNS infection including brain abscess, cavernous sinus thrombosis, epidural abscess, and meningitis in our institute.
  • During the same period, 18 NPC patients without CNS infection who were matched for tumor stage, age, and gender with the study group were randomly selected from the cancer registry at our hospital and enrolled as the control group.
  • RESULTS: The local tumor relapse rate, nasopharyngeal radiotherapy dose, and skull base osteoradionecrosis were all significantly higher in patients with CNS infection (p = 0.003, 0.011, and 0.001, respectively).
  • Although the incidences of otitis media and chronic rhinosinusitis were higher in patients with CNS infection, there were no significant differences between the two groups (p = 0.469 and 0.568, respectively).
  • The in-hospital mortality was 61.1%, and the overall mortality of CNS infection was 83.3%.
  • CONCLUSIONS: Postirradiated NPC patients with skull base osteoradionecrosis are prone to have CNS infection.
  • CNS infection is an adverse prognostic factor in postirradiated NPC patients.
  • [MeSH-major] Carcinoma / radiotherapy. Central Nervous System / radiation effects. Central Nervous System Infections / etiology. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Biopsy. Dose-Response Relationship, Radiation. Endoscopy. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors. Taiwan / epidemiology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19671259.001).
  • [ISSN] 1945-8924
  • [Journal-full-title] American journal of rhinology & allergy
  • [ISO-abbreviation] Am J Rhinol Allergy
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


98. Gill P, Litzow M, Buckner J, Arndt C, Moynihan T, Christianson T, Ansell S, Galanis E: High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system. Cancer; 2008 Apr 15;112(8):1805-11
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system.
  • BACKGROUND: Embryonal central nervous system (CNS) tumors (medulloblastoma, cerebral neuroblastoma, pineoblastoma, and primitive neuroectodermal tumors) are rare in adults.
  • The purpose of the current study was to evaluate adult patients with embryonal CNS tumors who were treated with HDC with ASCT and compare their outcomes with those of patients who received conventional-dose chemotherapy.
  • METHODS: The authors reviewed the medical records of 23 adult patients (age >or= 18 years) who were treated at the Mayo Clinic for recurrent embryonal CNS tumors between 1976 and 2004.
  • CONCLUSIONS: Improvements in the median TTP and survival noted with the administration of HDC with ASCT, as well as the acceptable toxicity of this regimen, supports consideration of its use in adults with recurrent embryonal CNS tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / drug therapy. Medulloblastoma / drug therapy. Neoadjuvant Therapy. Neoplasm Recurrence, Local / drug therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Carmustine / administration & dosage. Cisplatin / administration & dosage. Cohort Studies. Disease Progression. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Lomustine / administration & dosage. Male. Middle Aged. Procarbazine / administration & dosage. Retrospective Studies. Survival Rate. Thiotepa / administration & dosage. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer. 2008 Apr 15;112(8):1643-5 [18306390.001]
  • (PMID = 18300237.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 35S93Y190K / Procarbazine; 6PLQ3CP4P3 / Etoposide; 7BRF0Z81KG / Lomustine; 905Z5W3GKH / Thiotepa; Q20Q21Q62J / Cisplatin; U68WG3173Y / Carmustine
  •  go-up   go-down


99. Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH: Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer; 2007 Oct 1;110(7):1542-50
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
  • BACKGROUND: Effective chemotherapy is lacking for most types of central nervous system (CNS) tumors in children.
  • Temozolomide, an agent with activity against adult brain tumors, was investigated in children and adolescents with recurrent CNS tumors.
  • RESULTS: The cohort comprised 122 patients, including 113 with CNS tumors.
  • Among 104 evaluable patients with CNS tumors, 5 PRs and 1 CR were observed.
  • PRs occurred in 1 of 23 evaluable patients with high-grade astrocytoma, 1 of 21 with low-grade astrocytoma, and 3 of 25 with medulloblastoma/primitive neuroectodermal tumor (PNET).
  • No responses were observed in patients with ependymoma, brain-stem glioma, or other CNS tumors.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Astrocytoma / drug therapy. Central Nervous System Neoplasms / drug therapy. Child. Child, Preschool. Drug Administration Schedule. Ependymoma / drug therapy. Female. Humans. Infant. Male. Medulloblastoma / drug therapy. Neuroectodermal Tumors, Primitive / drug therapy. Treatment Outcome


100. Schrøder H, Kjeldahl M, Boesen AM, Nielsen OJ, Schmidt K, Johnsen HE, Gregersen H, Heyman M, Gustafsson G: Acute lymphoblastic leukemia in adolescents between 10 and 19 years of age in Denmark--secondary publication. Dan Med Bull; 2006 Feb;53(1):76-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Data seem to indicate that young adults with acute lymphoblastic leukemia (ALL) have a better survival when treated with pediatric protocols compared with adult ALL protocols.
  • RESULTS: There were no difference with respect to the distribution of T-ALL, CNS-leukemia, total white blood count and high risk chromosomal abnormalities between the two groups.
  • CONCLUSION: Young adult patients with ALL might benefit from therapy with pediatric NOPHO ALL protocols.
  • [MeSH-minor] Adolescent. Adult. Child. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Daunorubicin / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Male. Methotrexate / administration & dosage. Neoplasm Recurrence, Local. Prednisone / administration & dosage. Prognosis. Retrospective Studies. Stem Cell Transplantation. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16761337.001).
  • [ISSN] 1603-9629
  • [Journal-full-title] Danish medical bulletin
  • [ISO-abbreviation] Dan Med Bull
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down






Advertisement